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Summary
The studies described in this thesis were carried out in two phases. Studies were 
performed in rat and sheep hepatic microsome preparations and in rat lung 
microsome preparations in vitro. A pilot study to choose an optimum incubation 
time for studies using rat hepatic microsomes indicated that propofol, 28 pM, 56pM, 
84pM and 140 pM, was rapidly degraded, depending on the initial propofol 
concentration. For all subsequent studies, an incubation time of 15 min was chosen. 
There were no significant differences in the rate of degradation of propofol by 
hepatic microsomes at any propofol concentration between rats and sheep. The 
mean maximal velocity (Vmax; pmoles/min.mg of protein) and the mean Michaelis 
constant values (Km; pM) were 0.43 ± 0.04 & 48.9 ± 2.2 for propofol in rat 
preparations and 0.43 ± 0.06 & 42.4 ±7.1 for sheep tissues. However, the rate of 
degradation of propofol was significantly different between Sprague Dawley and 
Wistar rats (n=3 ; P < o .05). Microsome preparations obtained from lung tissue 
showed a high capacity of degradation of propofol (5.6, 11, 28 & 56 pM). However, 
the amount of cytochrome P450 present in lung microsomes could not be 
determined. The Vmax and Km values for lung tissue were 0.93 ± 0.28 
pmoles/min.mg of protein and 13.7 ± 4.8 pM , respectively.
1-aminobenzotriazole (12 mM), inhibited the degradation of propofol by rat hepatic 
microsomes by 75.4% - 29.5%, depending on the concentration of propofol assayed 
(28 - 140 pM), thus indicating that the degradation of propofol in this system is 
highly cytochrome P450-dependent.
Ketamine, 5 pg/ml, and alfentanil, 200 ng/ml, incubated with propofol (28 pM, 
56pM, 84pM & 140 pM) did not alter the rate of degradation of propofol in hepatic 
microsomes obtained from 6 Sprague Dawley rats. Mean (± sem) Vmax values 
(pmoles/min.mg protein) for propofol alone (P) and in the presence of ketamine (K) 
and alfentanil (A) were 0.52 ± 0.08 (P), 0.56 ± 0.06 (K); 0.43 ± 0.04 (P), 0.39 ±
0.03 (A). Mean (± sem) Km values (pM) for propofol alone (P) and in the presence 
of ketamine (K) and alfentanil (A) were 46.5 ± 2.5 (P), 53.2 ± 3.2 (K); 48.9 ± 2.2 
(P), 48.7 ± 4.4 (A). However, aminopyrine, 5mM, impaired the degradation of 
propofol at all concentrations. The mean (± sem) Vmax and Km values for propofol 
alone (P) and for propofol in the presence of aminopyrine (Am) were 0.42 ± 0.04 
(P), 0.43 ± 0.06 (Am) pmoles/min.mg protein and 43.6 ± 5.0, 66.2 ± 7.6 (Am) pM. 
The significant increase in Km value for propofol in the presence of aminopyrine (p 
< 0.05) indicates that the inhibition is competitive. Propofol (5.6pM, 56pM, 
280pM, & 561pM) also inhibited dose dependently the formation of formaldehyde 
from the demethylation of aminopyrine. Propofol, 56pM, impaired the 
demethylation of aminopyrine by 34.9% (mean), which suggests that propofol has
the potential in vivo to inhibit the degradation of drugs that are metabolised in this 
way.
Propofol, alone (group 1 (Gl), n=5) or in combination with ketamine (group 2 (G2), 
n=5) was used to anaesthetise 10 Scottish Blackface sheep undergoing superficial 
body surface surgery. All sheep were premedicated with acepromazine, 0.05 mg/kg 
and papaveretum, 0.4 mg/kg, i.m., 30 min before induction of anaesthesia with 
either propofol, 4 mg/kg (Gl) or propofol, 3 mg/kg, and ketamine, 1 mg/kg, injected
i.v. over 60 sec. Immediately after induction of anaesthesia, a variable infusion rate 
of either propofol alone (Gl), 0.3 - 0.5 mg/kg/min or propofol 0.2 - 0.3 mg/kg/min 
and ketamine, 0.1 - 0.2 mg/kg/min (G2) was started, adjustments being made 
according to the clinical and cardiovascular and respiratory status of each animal. 
Blood samples for propofol analysis, carried out by high performance liquid 
chromatography, were obtained during the infusion period and for 24 h after the 
infusion was stopped. The mean infusion periods were 64.8 ± 3.1 min and 60 ± 0 
min for Gl and G2 respectively. Induction and maintenance of anaesthesia was 
satisfactory for each group, although endotracheal intubation was not possible in 
one sheep in Gl after the induction dose of propofol. The inclusion of ketamine in 
the anaesthetic regime had a propofol - sparing effect. The total dose of propofol 
used was 801 ± 39 mg (Gl) and 468 ± 32 mg (G2), while the total dose of ketamine 
used was 267 ± 1 5  mg. There were no significant differences in pulse rates or 
systolic arterial blood pressures recorded during anaesthesia between the 2 groups, 
however, the respiratory rates were consistently higher in G2 than in Gl, although 
there was no evidence of respiratory depression in sheep in Gl. No attempt was 
made to measure the ’depth' of anaesthesia in either group.
Recovery from anaesthesia was rapid for animals in both groups. The mean time to 
assuming sternal recumbency was 6.3 ±1.2 min and 11.2 ± 1.7 min and to standing 
unaided was 10.9 ± 1.6 min and 15.1 ± 2.2 min for Gl and G2 respectively. The 
time to assume sternal recumbency was significantly longer for sheep in G2 
compared with sheep in Gl, however, the times to standing were not different.
The pharmacokinetics of propofol in sheep in Gl and G2 were described using non 
compartmental analsyses. The mean residence time, calculated for observed 
concentration values, was 0.71 ± 0.04 h and 0.71 ± 0.05 h, mean whole body 
clearance, 82 ±11 ml/kg.min and 129 ± 16 ml/kg.min, and the mean volume of 
distribution at steady state, 3.4 ± 0.5 L/kg and 5.46 ± 0.72 L/kg for Gl and G2 
respectively. There were no significant differences for these pharmacokinetic 
parameters between the 2 groups, although the group sizes were small (n=5). These 
data suggest that the concomitant administration of ketamine with propofol does not 
alter the pharmacokinetics of propofol in sheep.
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1. GENERAL INTRODUCTION
1
1 INTRODUCTION
General anaesthesia is a state of unconsciousness, produced by a process of 
controlled, reversible suppression of the central nervous system. General 
anaesthetics may then be defined as substances that cause a reversible loss of 
consciousness. They are used primarily to keep the patient unaware of, and 
unresponsive to, painful stimulation during surgical procedures. At the cellular level 
they inhibit the conduction of action potentials and the neurochemical transmission 
at synapses (Rang & Dale, 1991); but the mechanisms by which these effects occur 
are largely unknown (Miller, 1993). The occurrence of general anaesthesia involves 
three main neurophysiological changes, namely : unconsciousness; loss of response 
to painful stimulation (analgesia) and loss of motor reflexes (muscle 
relaxation).While the CNS changes induced by general anaesthetics are reversible, 
large doses of these agents can cause death due to loss of cardiovascular reflexes 
and respiratory paralysis. This is one of the reasons why a useful anaesthetic drug 
should permit rapid induction and recovery from anaesthesia and be easily 
controllable, thus making the level of anaesthesia easy to adjust during surgery.
General anaesthetic agents can be classified into two groups:
1. The inhalational anaesthetics: these may be either volatile liquids or gaseous 
agents which are delivered to the lungs.
2. The intravenous anaesthetics: a group of drugs which induce anaesthesia when 
administered intravenously, but can also be given by other parenteral routes.
1.1 INHALATION ANAESTHETICS
Since the introduction of nitrous oxide and diethyl ether, several other inhalation 
anaesthetics agents have been developed and used in men and animals. The first 
public clinical use of nitrous oxide was in 1845 for dental extraction, while ether 
anaesthesia was used publicly for removal of a tumour in 1846 by William Morton 
(Short, 1987). In 1847, chloroform was introduced into veterinary practice but, 
despite being a potent agent, it fell into disuse due to its toxicity (Hall & Clarke, 
1991). It was only after the discovery of halothane that the modem era of inhalation 
anaesthesia began in veterinary medicine.
The pharmacokinetics of inhalational anaesthetic agents are related to their 
physicochemical properties, such as the blood gas solubility, oil water solubility, 
and to physiological variables such as the alveolar ventilation and cardiac output 
(Hull, 1991). In healthy patients, the most important determinant of the speed of 
onset of, and recovery from anaesthesia, is the solubility of the drug in blood. The
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lower the blood solubility, the more rapid the induction of and recovery from 
anaesthesia. However, none of the inhalational agents can match the intravenous 
anaesthetics drugs for speed of induction of anaesthesia. Of all the inhalational 
anaesthetic agents, halothane, methoxyflurane and isoflurane are the most 
frequently used in veterinary practice.
Halothane (2-bromo-2 chloro-l,l,l-trifluorethane) is a halogenated anaesthetic 
discovered by Sweking in 1951 and introduced in veterinary anaesthesia in 1956 by 
Hall, becoming the most widely used inhalation anaesthetic (Short, 1987). It is a 
potent anaesthetic, providing a moderately fast induction of, and excitement-free 
recovery from anaesthesia (Adriani, 1970). If no other agents are administered, 
animals are able to walk without ataxia in 15-30 min, depending on the duration of 
anaesthesia (Hall & Clarke, 1991). Some 20-45% of the absorbed dose of halothane 
is biotransformed by oxidation, resulting in the formation of trifluoroacetic acid, 
chloride and bromide ions which are excreted in urine (Nunn et al., 1989). Dose 
dependent depression of cardiac output, arterial blood pressure and respiration have 
been observed with the administration of halothane in animals (Hall & Clarke, 
1991), although adaptation with time occurs for both cardiovascular and respiratory 
functions (Steffey et al., 1987). Bradycardia and arrhythmias are common during 
halothane anaesthesia. Hepatotoxicity has been reported following repeated 
administration or long periods of halothane anaesthesia in humans (Rang & Dale, 
1991), but, there are few similar reports in animals.
Methoxyflurane (2,2-dichloro-l,l-difluoroethyl methyl ether) is a halogenated 
ether, first introduced into veterinary practice in 1960 (Hall & Clarke, 1983). It is 
exceptionally potent, but due to its high blood solubility, induction and recovery 
from anaesthesia are slower than with halothane. Like halothane, it causes 
hypotension, but appears to produce better analgesia even at light surgical planes 
(Short, 1987). Methoxyflurane is extensively metabolised (50-75%) resulting in the 
formation of dichloroacetic acid, methoxy-difluoro acetic acid, oxalic acid and the 
release of fluoride and chloride ions as well as carbon dioxide (Nunn et al., 1989). 
Nephrotoxicity associated with high fluoride production is a considerable risk factor 
and it is manifested as large amounts of urine eliminated and the inability to 
produce concentrated urine (Holaday et al., 1970), consequently, its use has never 
become widespread.
Isoflurane (l-chloro-2,2,2- trifluoroethyl difluoromethyl ether), chemically related 
to enflurane, is the most recently introduced inhalant anaesthetic into veterinary 
practice, although as yet it is not commonly used in the UK. Isoflurane is highly 
volatile and has a low blood gas solubility coefficient, thus providing relatively
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rapid induction of, and recovery from anaesthesia as well as easy control of the 
depth of anaesthesia. Only 0.2% of absorbed drug is metabolised by oxidation and 
the main metabolites are trifluoroacetic acid and inorganic fluoride (Nunn et al., 
1989). Isoflurane-induced cardiovascular and respiratory depressant effects are 
dose-dependent, but tachycardia and reduction in cardiac output are less than with 
halothane, although hypotension is more profound (Higgs & Carli, 1983). 
Arrhythmias have not been reported with isoflurane, nor have nephro- or hepato- 
toxicity (Engelking et al., 1984; Gelman et al., 1984; Hall & Clarke, 1991).
In an attempt to increase the speed of induction of anaesthesia and reduce recovery 
times associated with inhalational agents, newer agents are being developed with 
lower blood gas solubility coefficients than isoflurane. Agents such as sevoflurane 
and desflurane, may prove useful in the future and are undergoing clinical trials in 
humans.
Nitrous oxide is the only inorganic inhalation anaesthetic gas used widely in clinical 
practice. Nitrous oxide is particularly rapid in action and appears to possess 
analgesic properties. However it is a weak anaesthetic agent in animals and, even at 
concentrations of 80% in the inspired air, it does not produce anaesthesia in any 
domestic animal species and therefore, cannot be used as a sole anaesthetic agent 
(Finck, 1984).
1.1.1 Advantages of the inhalation anaesthetics agents
In comparison with anaesthetic agents developed before halothane, the new 
anaesthetic agents, halothane, methoxyflurane and isoflurane have the advantage of 
being non-flammable and non-explosive substances in the range of concentrations 
used in clinical practice. They are also stable, useful for use in closed re-breathing 
circuits during prolonged administration periods, and are also more potent drugs 
(Hall & Clarke, 1983). The inhalational agents can be removed rapidly from the 
body in the event of an anaesthetic overdose, by altering ventilation and the inspired 
concentration. For halothane and isoflurane, elimination of the drug from the body 
does not rely entirely on metabolism, and consequently, disease states which alter 
drug metabolism profiles should not affect the course of anaesthesia.
1.1.2 Disadvantages of inhalation anaesthesia
Although recovery from most inhalational anaesthetic agents occurs rapidly, a 
desirable property in many situations, particularly for day-case surgery, almost all 
inhalation anaesthetics cause cardiovascular depression by their effects on the
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myocardium and blood vessels; while halothane in particular, sensitises the 
myocardium to adrenaline-induced arrhythmias (Johnston et al., 1976). A major 
disadvantage of inhalation anaesthetic agents is related to their physical 
presentation. As gases or volatile substances, they rapidly spread in the ambient air 
of the operating and recovery rooms which can cause a potential contamination of 
the working environment and may be hazardous for the operating personnel 
(Paddleford, 1987). This exposure can result in long term ill health (Vaisman, 1967; 
Cohen et al., 1980) and impaired psychomotor performance (Bruce et al., 1974). It 
has been considered that anaesthetists may metabolise halothane more extensively 
than other people, since they exhibit more breakdown products in their urine 
(Cascorbi et al., 1970) and a recurrent case of hepatitis in an anaesthetist due to 
halothane sensitisation has been reported (Klatskin, et al., 1969). Nitrous oxide can 
interfere with DNA synthesis at concentrations below those required for the 
production of anaesthesia, (concentrations which the anaesthetist may inhale in the 
operating room) (Nunn, 1987). Inhalation anaesthetic agents have been implicated 
as one of the causes of increased incidence of abortion among operating staff 
(Vaisman, 1967; Cohen et al., 1971). It has been agreed that most inhalation 
anaesthetics interfere with cell division (Sturrock & Nunn, 1975; Cullen, 1979), 
although this occurs at concentrations considerably higher than those required for 
anaesthesia. While scavenging systems employed in clinical practice limit it, total 
elimination of this hazard is considered impossible. Such a hazard does not occur 
with intravenous anaesthetic drugs.
1.2 INTRAVENOUS ANAESTHETIC AGENTS
Until recently, intravenous anaesthetic agents have not proved satisfactory for 
medium and long term maintenance of anaesthesia, but have been used almost 
exclusively for the induction of anaesthesia prior to maintenance with a gaseous 
agent or for anaesthesia of short duration. A major disadvantage of intravenous 
agents is the difficulty in controlling the depth of anaesthesia, because they cannot 
be recovered once injected. However, they have the advantage of acting rapidly, 
generally within 20 seconds, thus eliminating excitement before onset of 
anaesthesia. Intravenous anaesthetic drugs which have been used to maintain 
anaesthesia in veterinary practice include chloral hydrate, the barbiturates and 
alphaxalone/alphadolone combinations, but there are disadvantages associated with 
their use.
Chloral hydrate is a water soluble substance which has been used alone or as a 
mixture with magnesium sulphate or/and pentobarbitone (Hall & Clarke, 1983). It 
has serious disadvantages which have contributed to the decline in its use (Hall &
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Clarke, 1991). After injection its effects are slow to appear, and it produces 
profound cardiovascular depression when surgical anaesthesia is achieved, while 
perivascular injection causes severe tissue reaction. In veterinary medicine, chloral 
hydrate was used mainly for anaesthesia in horses.
Pentobarbitone was the first barbiturate to be used as a general anaesthetic in 
veterinary medicine in 1931. Originally it was administered orally or by 
intraperitoneal injection; by the end of 1938, slow intravenous injection of 
pentobarbitone became the routine technique for dogs and cats after Wright had 
used the technique successfully in more than 2000 patients (Hall & Clarke, 1983). 
Methohexitone sodium is another barbiturate which is two to three times more 
potent than thiopentone, with a shorter duration of action and more rapid recovery. 
Thiopentone sodium is the most widely used drug for inducing anaesthesia in dogs 
and cats, and is licensed for use in most domestic species. The duration and depth of 
thiopentone anaesthesia depend on the amount of drug injected, the speed of 
injection, the rate of distribution of the drug in non fatty tissues and the rate of 
uptake by body fat (Hall & Clarke, 1991). Thiopentone crosses the blood-brain 
barrier rapidly due to its high lipid solubility, and consequently, unconsciousness 
occurs within 15-20 seconds of administration (Brodie et al., 1952). The loss of 
consciousness is usually smooth, but the drug is unsatisfactory for producing 
surgical anaesthesia. Like other barbiturates it does not have analgesic properties 
(Briggs et al., 1982b) and therefore, deep anaesthesia is necessary to obtund 
nociceptive reflexes. Barbiturates are metabolised by oxidation mainly in the liver, 
but also to a small extent in the brain and kidney (Short, 1987). Metabolites of these 
drugs appear in the urine in the form of alcohols, ketones, phenols or carboxylic 
acids (Nunn et al., 1989). The clearance of thiopentone from the body is slow, 1.96 
ml/min.kg in dogs (Baggot et al., 1984) and the volume of distribution at steady 
state is large, 1.7 to 2.5 L/kg, due to extensive tissue uptake (Morgan et al., 1981; 
Hudson et al., 1983). The slow body clearance of thiopentone makes it unsuitable 
for use to maintain anaesthesia, as cumulation of the drug will rapidly occur (Hull,
1989). Barbiturates cause respiratory depression and apnoea is frequently observed 
after thiopentone injection (Bellman & Pleuvry, 1981). Rapid intravenous injection 
causes a fall in blood pressure and myocardial depression (Hall & Clarke, 1991). 
Perivascular injection of thiopentone causes local tissue necrosis and ulceration, 
sometimes with arterial spasm (Mazunder et al., 1980; Short, 1987).
Alphaxalone is a steroid drug with hypnotic properties which is virtually insoluble 
in water but dissolves in cremophor EL. The mixture with alphadolone, another 
steroid drug with less hypnotic properties, increases its solubility and has been 
called saffan (Hall & Clarke, 1991). Saffan is licensed for use as an anaesthetic for
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cats and primates. It causes mild hypotension but provides good muscle relaxation 
in the absence of severe respiratory depression. Saffan is not irritant if injected 
perivascularly. These properties make it a potentially useful agent for total 
intravenous anaesthesia, and indeed it was used for this purpose in humans (Sear & 
Prys-Roberts, 1979) although the potential to cause anaphylactic reactions in 
humans has led to its withdrawn in the U.K.. Anaphylactic reactions are commonly 
associated with this product in cats and potentially fatal hypotension induced by 
cremophor can occur in dogs due to massive histamine release (Hall, 1972; Eales et 
al., 1974). It is metabolised very quickly and the major route of excretion is via the 
bile (Middleton et al., 1982; Hall & Clarke, 1991).
The combination of the potent opioid agonist, etorphine and a phenothiazine 
tranquilliser, either methotrimeprazine (dogs) or acepromazine (horses) 
flmmobilon') can be classified as a neuroleptanalgesic drug mixture and may be 
considered an intravenous anaesthetic. It produces many undesirable side effects, 
respiratory depression, tonic convulsions in voluntary muscles and cardiovascular 
stimulation in horses, while in dogs, Immobilon induces respiratory depression and 
hypotension (Lees & Hillidge, 1976). Because of these undesirable side effects, its 
use is declining.
Ketamine [2 - (chlorophenyl) - 2 - (methylamino) - cyclohexane hydrochloride] 
developed in 1963, is a dissociative anaesthetic related to phencyclidine (Wright, 
1982). Its high therapeutic index, water solubility, compatibility with other drugs 
and lack of depressant effects on the CNS make it potentially useful in some 
circumstances (Short, 1987) but involuntary movements, sometimes even 
convulsions, during induction and recovery can occur, and during anaesthesia 
muscle tone is increased (Hall & Clarke, 1991). Ketamine causes increase in heart 
rate, cardiac output and arterial pressure, and produces only transient respiratory 
depression (Waterman & Livingston, 1978a; Short, 1987). Its major drawbacks are 
the observed hallucinations and delirium with irrational behaviour seen during 
recovery in humans, behavioural abnormalities have been also reported in dogs and 
horses (Nunn et al., 1989; Hall & Clarke, 1991). However despite its disadvantages, 
ketamine remains popular in veterinary medicine, for example it has been used in 
combination with other drugs for total intravenous anaesthesia in horses (Muir et 
al., 1978; Kaka et al., 1979; Taylor et al., 1992). Ketamine is metabolised in the 
liver by N-demethylation as the major pathway, resulting in the formation of nor- 
ketamine and dehydronorketamine, both active metabolites (Waterman & 
Livingston, 1978b).
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Propofol has proved to be a valuable addition to the limited range of drugs currently 
available for maintenance of anaesthesia. Because propofol is rapidly metabolised 
permitting a better and more rapid control of the depth of anaesthesia, it can be used 
for total intravenous anaesthesia (TIVA.).
1.2.1 PROPOFOL
1.2.1.1 CHEMISTRY, PRESENTATION AND USES
Propofol, 2,6 diisopropylphenol, is a relatively new intravenous anaesthetic agent, 
introduced into clinical practice for humans in 1980. It is one of a series of 
sterically-hindered alkyl phenols (James & Glen, 1980; Simons et al, 1988) that 
have anaesthetic properties in animals (Glen & Hunter, 1984). It is highly lipophilic, 
poorly soluble in water and virtually non-ionised at physiological pH (Simons et al, 
1988). Due to its insolubility in water, a solubilising agent is necessary to produce a 
preparation of the drug suitable for intravenous injection. It was first presented as a 
1% active solution in 16% cremophor EL (Langley et al, 1988; Simons et al, 1988; 
Kanto, 1988), but this formulation was associated with hypersensitivity reactions 
and pain around the injection site. Propofol is now formulated in Soya bean 
emulsion, 1% w/v aqueous emulsion in 10% soya bean oil, 1.2% egg phosphatide 
and 2.25% glycerol (Glen & Hunter, 1984; Langley et al, 1988; Kanto, 1988). It is 
widely used in human medicine, both for induction of anaesthesia prior to 
maintenance with inhalation anaesthetic agents and for total intravenous anaesthesia 
(for review see Langley et al, 1988). In veterinary medicine, propofol is licensed 
for use in the cat and the dog, but its use in other species either as a induction agent 
or for total intravenous anaesthesia, has been documented (Nolan et a l , 1985; 
Waterman, 1988; Reid et a l , 1993).
1.2.1.2 PHARMACODYNAMICS
The mechanism of action of propofol is not totally understood, however like the 
benzodiazepine and barbiturate groups of drugs, it appears to be linked to a site of 
action at the gamma amino butiric acid A receptor (GAB A a )  (Concas et a l , 1990; 
Hales et al., 1991 & Jewett et al., 1992).
When propofol is administered as a single bolus, the induction of anaesthesia 
depends on both the dose and the speed of injection. Roily et al. (1985) found that 
the mean induction time in humans was 50.5 seconds when 2 mg/kg was given over 
60 seconds, but this was reduced to 21.5 seconds when the period was reduced to 5 
seconds. Induction of anaesthesia with propofol is rapid, quiet, smooth and without 
excitement. Premedication with other drugs appears to decrease the amount of 
propofol necessary for induction of anaesthesia. Watkins et al. (1987) found that
premedication with acepromazine between 0.02 and 0.04 mg/kg reduced the overall 
induction dose of propofol from 5.95 to 3.81 mg/kg in dogs, a finding supported by 
Weaver & Raptopoulos (1990). The sensitivity to propofol seems to increase with 
age, and it has been suggested that this may be due to a decrease in hepatic 
enzymatic activity. It was reported that doses of at least 2.25 mg/kg were necessary 
for successful induction of anaesthesia in younger patients (less than 60 years) 
while in the elderly, doses between 1.25 - 1.75 mg/kg were adequate (Langley et al., 
1988). Recent work in dogs in Glasgow Veterinary School, indicated that in dogs 
over 8 years of age the dose of propofol required to induce anaesthesia was less than 
in dogs less than 5 years old (5 mg/kg cf 6.5 mg/kg) (Reid, personal 
communication).
Propofol administration may be associated with pain at the injection site. Grood et 
al (1985) reported that 6 patients out of 30 complained of pain during propofol 
injection, and Kirkpatrick et al (1988) observed pain which varied from mild to 
moderate in 7 patients out of 24 during propofol injection. Weaver & Raptopoulos 
(1990) observed involuntary movements during induction of anaesthesia with 
propofol in 1 out of 89 dogs which they suggested might have been a sign of pain.
Patients recover very quickly from propofol anaesthesia and do not usually suffer 
hangover effects. Grood et al (1985) reported that the mean time to eye opening in 
humans after infusion was 10.5 minutes, while the time to orientation and adequate 
answers to question was 11.5 minutes. Watkins et al (1987) also reported rapid 
recovery times after maintenance with intermittent injection in dogs, 18 min in 68 
unpremedicated dogs and 22 min in 65 premedicated animals after the 
administration of the last dose, with one particular feature of the recovery being the 
absence of any residual ataxia. Following a 60 min zero order infusion of propofol 
in 7 dogs undergoing surgery, Nolan and Reid (1993) reported a rapid return of 
consciousness and ability to stand unaided. The high volume of distribution and 
rapid clearance are the main factors which determine the decline in propofol 
concentrations necessary for recovery of consciousness (Cockshott et al, 1990; 
Nolan et al, 1993; Reid et al, 1993).
Studies in animals have demonstrated that propofol has effects on the cardiovascular 
system. Glen & Hunter (1984) reported that single intravenous doses of propofol, 
3.75 mg/kg, administered to mini-pigs, increased the heart rate and cardiac output, 
and decreased the mean arterial blood pressure and total peripheral resistance in the 
early minutes of administration. In humans, decreases in systolic and diastolic blood 
pressures have been observed also during the early stages of anaesthesia. 
Kirkpatrick et al (1988) reported hypotension following induction in 4 out of 24
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patients. Goodchild et al. (1989) suggested that in humans cardiac output and 
arterial pressure are well maintained at normal anaesthetic blood propofol 
concentrations if the preload is maintained; a suggestion also made by Kirvela et al.
(1992). The concomitant administration of propofol, 2.5 mg/kg and alfentanil, 3 
pg/kg, caused a greater decrease in the mean arterial blood pressure than when 
propofol was administered alone (24 vs 45 mm Hg) (Van Aken et al., 1986). The 
initial hypotensive effects of propofol may be advantageous in humans during the 
intubation period, because it has been observed that propofol does not increase the 
mean peak of systolic arterial blood pressure post intubation, and in some cases it 
appears to lower it (Monk et al., 1987). This contrasts with other anaesthetic drugs 
which usually increase the arterial blood pressure following intubation. In dogs, 
hypotension was recorded during propofol infusion, with a maximum effect (20% 
decrease) 5 min after induction of anaesthesia (Nolan & Reid, 1993).
Propofol causes apnoea post induction in both humans and animals. Grood et al. 
(1985) observed apnoea in all patients (19 women and 11 men) who had total 
intravenous anaesthesia with propofol combined with fentanyl and vecuronium. 
Morgan et al. (1989) recorded apnoea in 5 out of 207 cats and 6 out of 290 dogs, 
and Nolan et al. (1993) noted an incidence of 25% after induction of anaesthesia in 
dogs. Although this apnoea is usually of short duration, about 60 seconds or less, it 
can in some cases last considerably longer and opioid drugs may enhance this 
respiratory depression (Goodman et al., 1987; Nolan & Reid, 1993). The incidence 
and occurrence of apnoea may be related to the speed of drug injection. Watkins et 
al. (1987), suggested that when propofol is administered slowly (over 10 to 40 
seconds) apnoea is less evident.
Nolan & Reid (1993) observed respiratory depression throughout anaesthesia in 
spontaneously breathing dogs which received propofol infusions for anaesthesia. 
The dogs had end tidal pressure of carbon dioxide values in excess of 5.3 kPa 
throughout the infusion period, however, this did not persist into the recovery 
period. Hall & Chambers (1987) also observed respiratory depression, in dogs 
anaesthetised with propofol infusions, with PaCC>2 values ranged from 4.9 to 8.1 
kPa during anaesthesia. Ponies premedicated with xylazine (0.5 mg/kg iv) in which 
anaesthesia was induced with propofol (2.0 mg/kg iv) and maintained with two 
infusion rates of propofol (0.15 mg/kg/min and 0.2 mg/kg/min), showed respiratory 
depression which was characterised by a decrease in rate and an increase in arterial 
carbon dioxide tension (PaCC>2 above 41 mm Hg throughout infusion) (Nolan & 
Hall, 1985). Despite the respiratory depression associated with propofol 
administration, its use is not precluded in spontaneously breathing patients where 
there is not pre-existing respiratory dysfunction.
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The analgesic properties of propofol are controversial, but it may be better in this 
respect than thiopentone. Briggs et al. (1982b) suggested that administration of 
subanaesthetic doses of propofol had an analgesic effect in 35%, anti-analgesic 
effect in 5%, and no effect in 60% of patients, while thiopentone was anti-analgesic 
in 60%, had no effect in 30% and was analgesic in only 10% of patients. It has also 
been reported that the incidence of nausea and vomiting with propofol is low, with 
suggestions that it might have some anti-emetic properties (McCollum et al., 1987), 
however, Hall & Chambers (1987) observed that 16% of dogs vomited following 
anaesthesia with propofol infusions.
1.2.1.3 PHARMACOKINETICS
Pharmacokinetics describe the relationship between the administration, distribution 
and the magnitude of the concentration, in different regions of the body, of a given 
drug (Pratt, 1990). Pharmacokinetic parameters represent the mathematical 
description of changes in drug concentration within the body (Baggott, 1977). The 
pharmacokinetic characteristics of a drug determine its access to the site of action.
The disposition of a drug in the body is described by four phases namely, 
absorption, distribution, metabolic alteration and excretion. In order to have an 
effect, a drug must first enter the blood, unless it acts directly at the site of 
administration. Subsequently it reaches the tissues at a rate determined by the blood 
flow through each specific organ (Pratt, 1990). During this process some of the drug 
molecules might be bound to plasma proteins, which may influence its distribution 
and metabolism. Pharmacokinetic studies can be done using compartmental or non 
compartmental analyses. The compartmental model, assumes the body as a system 
of distribution compartments (one, two or three) with mathematical, but not 
physiological meaning (Baggot, 1977). It assumes that a drug once absorbed, 
distributes quickly and homogeneously into the central compartment, which consists 
of the blood and well perfused tissues. Distribution then takes place more slowly to 
the peripheral compartments. It is assumed that elimination takes place from the 
central compartment only (Baggot, 1977; Hull, 1991).
The non compartmental model is based on the theory of statistical moments, which 
represent the times taken for individual drug molecules to pass through the body 
before elimination. This movement of drug molecules is assumed to be proportional 
to its concentration gradient in the distribution and elimination compartments (Hull, 
1991). For the optimal use of an intravenous anaesthetic agent, particularly where 
an infusion regime is to be established, detailed pharmacokinetic evaluation is 
critical (Ghoneim et al., 1977; Kanto et al., 1988) because it might be influenced by
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both premedication and inhalation anaesthetics (Langley et al., 1988) and also by 
other drugs that may be used during anaesthesia.
Many pharmacokinetic studies of propofol have been carried out in humans, and it 
appears that propofol has many advantageous kinetic properties when compared to 
other intravenous anaesthetics agents, which explain its usefulness by bolus for 
induction of anaesthesia or as a continuous infusion for maintenance of anaesthesia 
and sedation in intensive care units (Mendoza et al, 1992). Its pharmacokinetic 
parameters do not depend on the speed of injection, dose, sex or body weight 
(Adam et al., 1983; Kay et al., 1986; Kanto et al., 1988). The pharmacokinetic 
profile of propofol makes it suitable for administration by a combination bolus and a 
variable-rate infusion technique, which permits the anaesthetist to titrate the 
propofol dose to the desired clinical effect (Shafer et al., 1988).
After a single bolus injection or infusion for maintenance of anaesthesia, propofol 
distributes extensively to the central nervous system (CNS) and other tissues such as 
muscle and fat (Langley et al., 1988; Kanto et al., 1988). In most studies, the blood 
concentration versus time data is best described by a three compartment model with 
the data from some individuals fitting a 2 compartment model. Gepts et al. (1987), 
studying the behaviour of a constant rate infusion at 3, 6, and 9 mg/kg/h in humans 
with a mean body weight of 75kg, 65.5kg and 61.6kg respectively, found that for all 
three rates the pharmacokinetic profile of propofol was best described by a three 
compartment open model with central elimination. Simons et al. (1991b) using rat, 
dog and rabbit as experimental models, given a radioactive bolus dose of propofol 
(7-10 mg/kg) intravenously (rat, dog, rabbit) or a continuous infusion (0.47 
mg/kg/min) in the dog, reported that the plasma concentration-time relationship was 
best described by a three compartment open model in the rat and dog, but by a two 
compartment model in rabbits. Reid et al. (1993) also reported that the blood 
propofol concentration-time data for goats was best described by a two 
compartment model.
Propofol has a very large volume of distribution reflecting extensive tissue 
distribution, which is probably related to its high lipophilicity. In humans, mean 
volumes of distribution at steady state (Vdss) of 287 ± 213 L and up to 1666 ± 756 
L have been reported (Gepts et al., 1987; Albanese et al., 1990). Simons et al. 
(1988) described extensive distribution, after a single dose of propofol. In dogs 
Vdss values around 6.51 L/kg have been reported which are higher than reported by 
some authors in humans (Nolan & Reid, 1993). Reid et al. (1993) similarly reported 
widespread distribution and a large Vdss (mean 2.56 L/kg) in goats. Large variations 
have been reported for the half life of propofol which has been suggested to be
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related to the length of the sampling period (Campbell et al., 1988). In studies 
where 2 compartment model was used, the elimination half life values ranged from 
92 to 106 min (Schuttler et al., 1985, 1986; Simons et al., 1988), when a three 
compartment model was used the elimination half life was observed to be biphasic, 
the first stage was rapid with a half life of 25 to 56 min while the terminal phase 
was longer with a half life of 184 to 309 min. (Cockshott et al., 1987; Gepts et al, 
1987) and indeed half-lives of up to 44-47 h have been reported (Morgan et al.,
1990). It has been suggested that prolonged infusion periods (Albanese et al., 1990; 
Morgan et al., 1990), length of the sampling period (Campbell et al., 1988 ; 
Albanese et al., 1990), and the severity of the surgery (eg: abdominal surgery) 
(Shafer et al., 1988) can prolong the elimination half-life of propofol.
Propofol is rapidly cleared from the body, with clearance values in humans varying 
from 1.7 L/min to 2.2 L/min (Cockshott et al., 1985; Gepts et al., 1987; Simons et 
al., 1988; Albanese et al. 1990). Nolan & Reid (1993) reported that in dogs, body 
clearance (50.1 ml/kg.min) was similarly high, while Reid et al. (1993) in goats, 
reported that clearance (275 ml/min.kg) was vastly in excess of liver blood flow. 
Due to the high body clearance values observed it has been suggested that an extra 
hepatic site of metabolism cannot be excluded (Simons et al., 1991a). Gray et al.
(1992) proposed an extra hepatic site of metabolism of propofol, after their findings 
that only 42%-89% of blood propofol radioactivity was unchanged propofol during 
the anhepatic phase of anaesthesia in six patients undergoing hepatic transplantation 
given a bolus injection of propofol. Two patients showed evidence of propofol 
glucuronide and 4-quinol sulphate during the same phase indicating that metabolism 
of propofol was occurring elsewhere. Veroli et al. (1992) also reported the 
appearance of a propofol metabolite and did not detect unchanged propofol in the 
urine of 10 patients, during the anhepatic phase of orthotopic liver transplantation, 
further evidence of extra hepatic metabolism of the drug. Simons et al. (1988) and 
Shafer et al. (1988) also proposed extrahepatic metabolism of propofol after 
recording clearance values of 2.2 L/min and 2.09 ± 0.65 L/min respectively in 
humans, values in excess of liver blood flow. It was suggested by Nolan & Reid
(1993) and by Reid et al. (1993) that extrahepatic clearance might occur in dogs and 
goats since total body clearance values recorded in these species were similarly in 
excess of liver blood flow values for these species.
Studies with propofol in humans and experimental animals have shown that 
individual variation in blood concentrations of propofol may occur (Schuttler et al., 
1988; Puttick et al., 1992). Despite an identical zero-order infusion rate of propofol 
in 7 dogs undergoing surgery, considerable between animal variation in blood 
propofol levels were observed and in blood concentrations required to maintain
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anaesthesia for surgery (Nolan & Reid, 1993). In humans, there seems to be also a 
wide variation in blood propofol levels. (Gepts et al., 1987) administered propofol 
to patients by continuous infusion at a maximum rate of 0.15 mg/kg and found that 
there was an initial increase in blood concentration over 10 min, followed by a 
slower rate of increase over the infusion period. Recovery from anaesthesia has 
been observed at propofol concentrations of 0.98±0.04 to 1.96±0.18 pg/ml in 
humans and 1.7 to 2.7 pg/ml at head lift in dogs (Cockshott et al., 1990; Nolan & 
Reid, 1993). In some patients a small secondary peak in blood propofol 
concentration has been observed at the time of regaining consciousness (Cockshott 
et al., 1987; Kay et al., 1986; Schuttler et al., 1985).
Other drugs are frequently administered during anaesthesia in humans and animals 
which may influence the distribution and metabolism of the anaesthetic agent 
propofol. Cockshott et al. (1987) reported that the opioid analgesic fentanyl reduced 
the volume of the central compartment (Vc) by 46% and increased the half life 
(11/215) °f  propofol by 24%. In contrast, Nolan et al (1993) reported that 
maintenance of anaesthesia with halothane and nitrous oxide in dogs had no effect 
on the pharmacokinetics of propofol administered as an intravenous bolus. They 
reported clearance values of 58.6 and 56.3 ml/kg.min and Vdss of 4889 and 4863 
ml/kg for propofol alone and propofol with halothane and nitrous oxide 
respectively. It has also been suggested that in humans premedication and other 
drugs do not affect the rapid recovery from (Morgan et al., 1989), and the good 
induction of (Briggs et al, 1982a; Morgan et al., 1989) anaesthesia with propofol.
Pathology may influence the pharmacokinetics of propofol. Audibert et al. (1993) 
suggested that inflammatory reaction in vivo prolonged the elimination half-life of 
propofol, but did not change its clearance or volume of distribution, while hypoxia 
decreased propofol clearance and as a consequence, the elimination half-life was 
increased.
The pharmacokinetics of propofol given by infusion, are not markedly affected by 
moderate cirrhosis and recovery, measured as the time of eye opening, occurs at 
similar blood propofol concentration in healthy patients and in those with cirrhosis 
(Kanto et al., 1988; Servin et al., 1988). In a later report, Servin et al. (1990) 
reported a reduction although not significant in total body clearance of propofol in 
patients with cirrhosis (1.56±0.48 L/min in cirrhotics and 1.75±0.32 L/min in non 
cirrhotics) and a significantly greater Vdss (202±82 L) than in non cirrhotic group 
(121±49 L), but the terminal half life was not altered.
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Metabolism of propofol
After absorption into the body, many drugs undergo chemical reactions which 
change their physical properties and biologic effects. Drug metabolism is normally 
divided into two phases, phase I (or functionalisation reactions) and phase II (or 
conjugative reactions). Phase I metabolism, includes oxidation, reduction, 
hydrolysis and hydration reactions; in most cases the final product contains a 
reactive group, prepared for the phase II reactions (Gibson & Skett, 1994). 
Metabolic reactions usually affect the polarity of the compound, altering the way in 
which it is distributed and excreted from the body while in some cases, this 
metabolism is required for therapeutic effect.
Propofol is rapidly metabolised, mainly by the liver, and the urine is the major route 
of excretion in most species including humans. According to Massey et al. (1990) 
88% of propofol administered to humans is metabolised in this way. Following an 
intravenous bolus dose of radioactive propofol to men, 88% of the radioactivity 
was recovered in the mine in five days and about 2% in faeces, with less than 0.3% 
excreted unchanged (Simons et al., 1988). Simons et al. (1991b) reported that only 
52-85% of radioactive propofol was found in the circulation 2 min after bolus
i.v. administration to dogs, rats, and rabbits. Radioactivity was detected in the urine 
60-95%, but 13-31% was detected in faeces of rats and dogs. Simons et al. (1991a) 
suggested that only 2% of the propofol dose administered to female rats remained in 
the body tissues 24 horns after dosing. Simons et al. (1988) and Simons et al.
(1992) described glucuronic acid conjugate of propofol (propofol glucuronide) and 
glucuronic acid and sulphate conjugates of its hydroxylate derivative, 2,6- 
diisopropyl-l,4-quinol (1 & 4-quinol glucuronide, 4-quinol sulphate) to be the 
major metabolites in man, with the glucuronide accounting for about 53% of the 
urinary radioactivity. These metabolites have been also reported to be present in rat, 
dog and rabbit by Simons et al. (1991b), while in the same study trace amounts of 
propofol sulphate were detected in rabbit urine.
1.2.2 TOTAL INTRAVENOUS ANAESTHESIA (TIVA)
In order to eliminate the potential hazards of environmental pollution, the use of 
intravenous anaesthetic agents for the maintenance of anaesthesia is becoming a 
popular technique in humans. In addition the technique is easy to perform and 
greater control of the depth of anaesthesia can be afforded using closed loop circuits 
(Schuttler et al., 1988). Since there is more scope for the development of new
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intravenous drugs compared with those given by inhalation, it is likely that research 
will concentrate on the development of such agents with better pharmacological 
characteristics and potential for use in a total intravenous technique.
Recovery from anaesthesia is determined by the kinetic profile of the drugs used. If 
the drug is metabolised rapidly in the body, recovery from anaesthesia can be 
quicker than that seen with inhalation anaesthetics and consequently, such a drug 
would be useful for total intravenous anaesthesia. Older intravenous agents such as 
thiopentone are unsuitable for TIVA, because they are slowly metabolised in the 
body, and recovery from anaesthesia is slow after repeat administration or long 
infusions (Hull, 1989). In contrast propofol, has been shown to be rapidly 
metabolised and cleared from the body, which affords a good control of the depth of 
anaesthesia during the course of surgery and rapid recovery once drug 
administration is stopped.
An ideal intravenous anaesthetic should produce a rapid onset and short duration of 
action and inactivation by metabolism. It should possess no cumulative properties, 
minimal cardiorespiratory effects, analgesic properties and be stable in solution as 
well as soluble in water. It should not cause histamine release after injection, no 
tissue damage if injected perivascularly or venous damage (Dundee, 1979). 
Although propofol does not fulfill all the properties of an ideal intravenous 
anaesthetic, since it depresses the cardiovascular and respiratory systems, has 
minimal analgesic properties, is not stable in solution and is not soluble in water, if 
used properly these disadvantages can be overcome and propofol is the agent most 
suitable for TIVA to date.
However, there are disadvantages associated with a total intravenous technique. It 
requires specialised equipment such as an infusion pump and good venous access. 
In addition the influence of drugs given concurrently can alter the rate of 
metabolism of the anaesthetic agent giving rise to prolonged recovery (Reid & 
Nolan, 1992).
1.3 IN  VITRO DRUG METABOLISM STUDIES
For better understanding of drug metabolism, drug interactions and other aspects 
related to drug administration, a good knowledge of the enzymatic processes and 
organs involved is important. These studies are not always possible to carry out in 
vivo, for ethical, economic and scientific reasons. Studies carried out in vitro, permit 
the investigation of a specific biotransformation pathway under strictly controlled 
conditions, allow the use of very high drug concentrations (Klooster, 1992), and
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provide useful background information on how to approach and what to expect 
during in vivo studies.
In vitro studies of drug metabolism have limitations since many factors which 
influence the response in vivo are absent. However, such techniques are still very 
useful and important. Much fundamental knowledge regarding the molecular 
mechanisms affecting drug disposition, has been obtained using liver tissue in vitro 
since it is the main site of drug metabolism (phase I and phase II reactions) and 
detoxification.
Studies of drug metabolism in vitro can be carried out using techniques and tissues 
such as: organ perfusion, tissue slices, separated cell suspensions, tissue 
homogenates, tissue cultures (e.g. hepatocellular cultures), subcellular fractions 
(microsomal and cytosolic cell fraction preparations), solubilisation and purification 
of enzymes. The most commonly used tissues are the microsomal fraction 
preparations. The first description of metabolism of a foreign compound by hepatic 
microsomes was made by Mueller and Miller in 1953, and since this time, hepatic 
microsomes have been used widely.
Microsomal preparations are small bodies of homogenised endoplasmic reticulum of 
any group of cells, but mainly of the liver, kidney, lung and intestine. The main 
enzymatic system is the mixed-function oxidase system, cytochrome P450, which 
exists as multiple forms or isoenzymes, and to date, more than 200 different 
cytochrome P450s have been identified (for review see Soucek & Gut, 1992; 
Gibson & Skett, 1994). They are subdivided into gene families and gene subfamilies 
according to their similarity. The cytochrome P450 enzyme system performs a great 
variety of phase I reactions involving many structurally diverse drugs and 
chemicals, whose only common feature is a reasonable degree of lipophilicity 
(Mannering, 1971; Gibson & Skett, 1994). All reactions occur in the presence of 
molecular oxygen and NADPH. The activity of the microsomal enzymatic system 
can be affected by factors such as sex, nutrition, diurnal variation, species, breed, 
age, liver pathology, animal bedding, stress, insecticides, ambient temperature and 
cage crowding (Gibson & Skett, 1994).
The use of microsomal preparations has many advantages, firstly, the methodology 
is relatively simple and inexpensive; material can be preserved for long periods of 
time with little loss in enzyme activity; the method facilitates the study of specific 
biotransformation steps and finally, the preparation costs less than that of 
hepatocytes, especially for interspecies studies. The disadvantages of the use of 
microsomal preparations are mainly because they do not take into account the 
uptake of drugs by the cells; there is a loss of some biotransformation enzyme
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systems (example the cytosolic); it needs a continuous supply of NADPH 
generating system and in general, the incubation cannot be prolonged for more than 
one hour.(Mannering, 1971).
1.4 AIMS OF THIS STUDY
The pharmacokinetic properties of propofol (Cockshott et al., 1985), are such that it 
has potential advantages, especially for day case surgery in humans and animals 
where a rapid recovery from anaesthesia is desirable. This latter feature is a 
particular requirement for ruminant species in order to minimise the risk of 
regurgitation and tympanism (Waterman, 1988), and for brachycephalic breeds of 
dogs and all animals where a rapid return of consciousness is desirable. Total 
intravenous anaesthesia (TIVA) offers many advantages over inhalational 
anaesthesia and to this end, propofol appears to be the intravenous anaesthetic most 
suitable. However, propofol has some undesirable side effects and consequently, 
supplementation with other drugs during propofol anaesthesia is necessary in order 
to improve the quality for surgery. Drugs commonly used concomitantly with 
propofol in humans include alfentanil, a p opioid receptor analgesic which produces 
excellent suppression of responses to surgical stimuli and has little effect on the 
cardiovascular system (Schuttler et al., 1988). These workers reported that computer 
controlled infusions of alfentanil and propofol given to 20 patients undergoing 
surgery, produced satisfactory conditions for both minor and major surgical 
stimulation and that recovery from anaesthesia was rapid. This combination has 
been infused in dogs undergoing thoracic surgery (Flecknell et al., 1990) although 
bradycardia was a considerable problem. However the major disadvantage of 
alfentanil is its depressant effect on the respiratory system and consequently, its use 
by infusion is not recommended in spontaneously breathing patients. Since most 
surgical procedures in animals are performed in spontaneously breathing animals it 
was considered appropriate to investigate drugs which would complement propofol 
infusions, without depressing the respiratory systems. Ketamine apperead to be a 
drug worthy of study for several reasons. Firstly, it does not depress the 
cardiovascular or respiratory systems in animals, indeed it may cause cardiovascular 
stimulation (Waterman & Livingston, 1978a). Secondly, it is considered to be a 
good analgesic both in humans and in many animal species (Sparks et al., 1973) and 
thirdly, the pharmacokinetics of ketamine reported in animals (Heaver & Bloedow, 
1979; Kaka et al., 1979; Waterman & Livingston, 1978a) indicates that is rapidly 
cleared from the body and suggest that it would be suitable for infusion regimens. 
Disadvantages of ketamine use include the possibility that it might alter the 
metabolism of propofol, since ketamine has been shown to induce liver enzyme
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activity in rats (Livingston & Waterman, 1978) and if used inappropriately might 
cause convulsions and delirium as has been reported in dogs (Hall & Clarke, 1991).
The aims of this thesis were firstly, to study the degradation of propofol by hepatic 
microsomal enzymatic systems in two species, rat and sheep, particularly the 
cytochrome P450 system; with this information it was then considered of interest to 
study potential interactions in vitro between propofol and other drugs metabolised 
by the same enzymatic system, in particular ketamine and alfentanil, drugs which 
might be coadministered with propofol during anaesthesia. Since it had been 
suggested that propofol might undergo extrahepatic degradation it was considered 
appropriate to study other potential sites of degradation. Finally, it was decided to 
study the use of propofol/ketamine infusions using sheep as a model.
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2. MATERIALS AND METHODS
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2.1 D e g ra d a t io n  a n d  in te ra c t io n  o f  p ro p o fo l  w ith  
o th e r  d r u g s  in vitro
2.1.1 Animals
Adult healthy Sprague Dawley or Wistar rats, weighing between 400 and 450 grams 
were used for the preparation of hepatic or lung microsomal specimens. The animals 
were housed in groups of six, on sawdust bedding, at a constant temperature of 
23°C and on a twelve hour light: dark cycle. They were allowed free access to food 
and water.
Sheep hepatic microsomes were prepared from livers of healthy adult Scottish 
Blackface sheep obtained from a local abattoir.
All studies were carried out with rat microsomes, unless otherwise stated. Each 
experiment was carried out in replicates of six rats and each concentration was done 
in duplicate. The exceptions to this were for the study of propofol degradation by 
lung microsomes where five rats were used, and the time course pilot study where 
two determinations from one animal only was used at each time point.
2.1.2 Preparation of hepatic microsomal specimens
All chemicals were purchased from Sigma Chemicals Co., Dorset, England, unless 
stated otherwise.
Sodium chloride (Analar, BDH Chemicals Ltd, Poole) was used as 0.9% solution in 
distilled water. Potassium chloride (Analar BDH Chemicals Ltd, Poole) was used as 
a 1.15% solution in distilled water. Tris buffer was prepared from the mixture of 
trizma hydrochloride and trizma base, as a 0.1M solution, pH 7.4, containing 20% 
(v:v) glycerol. Before the preparation of microsomes, all tubes, the homogeniser, the 
solutions, the centrifuge rotors, and other material used for the preparation of 
microsomes were cooled at -20°C for approximately 45 min.
Hepatic microsomes were prepared according to the method of Rutten et al. (1987) 
with some minor modifications. Briefly, the rats were killed by cervical dislocation, 
the abdomen was incised with a scalpel blade and a catheter was inserted into the 
hepatic portal vein. The liver was then washed in situ with approximately 300 ml of 
ice cold sodium chloride, 0.9%, injected through the catheter to remove excess 
blood. After washing, the liver was excised, freed of connective tissue, weighed, 
placed in 3 volumes of ice cold potassium chloride, 1.15%, finely sliced and 
homogenised, using a Potter-Elvehjem glass Teflon homogeniser (5 complete passes 
with the pestle). Once the tissue was collected, all subsequent procedures were
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carried out at 0-4°C. The liver homogenate was centrifuged at 9000 g for 20 min in 
an ultra centrifuge (Beckman Instruments, INC., California) at 2°C, in order to 
remove cell debris, nuclei and mitochondria. The floating fat layer was carefully 
removed with a spatula and the underlying supernatant fraction was decanted into 
ultra-clear centrifuge tubes and recentrifuged at 105000 g for 75 min, at 2°C. The 
cytosolic fraction (supernatant) was discarded and the precipitate (microsomal 
pellets) was resuspended carefully using an ultra Turrax (Janke & Kunkel GmbH & 
Co, Germany) in 12 ml of Tris buffer (0.1M, pH 7.4), containing 20% glycerol. The 
resuspended microsomes were divided into aliquots (1 ml), frozen immediately in 
liquid nitrogen and stored at -80°C until used within 15 days of preparation. Three 
hundred pi of the microsomal suspension was used for protein and cytochrome 
P450 measurements, which were carried out on the same day the microsomes were 
prepared.
For sheep liver microsomes, the caudate lobe was collected into ice cold sodium 
chloride, 0.9%, within 15 min of death and placed in a bucket with ice. The liver 
was then washed with approximately 300 ml of ice cold sodium chloride, 0.9%, 
through a catheter which had been placed into the central vein of the lobe. After 
washing, microsomes were prepared as described for rats {vide supra).
Protein measurement
Microsomal protein concentrations were measured using a commercially available 
kit (Sigma Chemical Co., Dorset England) which is based on the method reported 
by Lowry and colleagues in 1951. Briefly, 0.125, 0.250, 0.500, 0.750 and 1.000 ml 
of a protein standard solution (bovine serum albumin, fraction V) were diluted 
(where appropriate), to 1 ml with water to yield protein concentrations of 50, 100, 
200, 300 and 400 pg/ml respectively. Microsomal suspensions (10 pi) were diluted 
similarly to 1 ml with water and a blank tube was prepared with 1 ml of water, 
corrected to the same glycerol concentration present in the sample tubes. One ml of 
Lowry reagent solution was added to all tubes, the tubes vortexed and allowed to 
stand for 20 min at room temperature (approximately 20°C); 0.5 ml of Folin & 
Ciocalteu's phenol reagent were then added to each tube and the tubes vortexed 
again. Colour was allowed to develop at room temperature for 30 min. The tube 
contents were subsequently transferred to 3 ml quartz cuvettes and the absorbance 
of the solution at 750 nm read using an ultraviolet/visible (UV/Vis) 
spectrophotometer (Pye Unicam Ltd, Cambridge). All standards and samples were 
assayed in duplicate.
A calibration curve was prepared by plotting the absorbance of the standards against 
their respective protein concentrations. The protein concentration of the samples
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was determined from the calibration curve and the result was adjusted according to 
the dilution factor in order to calculate the protein concentration in the original 
sample.
Cytochrome P450 determination
The cytochrome P450 (cyto P450) concentration in the microsome preparations, 
was determined using the method developed by Omura and Sato (1964) and 
described by Gibson and Skett (1994). This method is based on the ability of cyto 
P450, a haemoprotein, to bind to carbon monoxide (CO) which yields a 
characteristic absorption spectrum at 450 nm when the haem iron is reduced. A 
molar extinction coefficient of 91 mM'^cm^ (for the wavelength couple 450-490 
nm) and a cuvette path length of 1 cm were used to convert absorbance units to 
nmoles of cyto P450 as follows: (absorbance difference (450-490 nm) * cuvette 
path length)/extinction coefficient = nmoles of cyto P450/ml of the diluted sample. 
Once the concentration of protein in the original microsomal suspension is known 
the concentration of cyto P450 per mg of protein can be calculated as follows: (cyto 
P450 in the diluted sample * dilution factor)/protein content in the original sample = 
nmoles cyto P450/mg of protein. Briefly, 200 pi of microsomal protein were diluted 
20 times (up to 4 ml), with Tris buffer, 0.1M, pH 7.4 containing 20% (v:v) glycerol. 
Two ml of the sample were transferred to both matched sample and reference 
cuvettes and the absorbance baseline was recorded between 400 nm and 500 nm 
using an UV/Vis spectrophotometer. The sample and reference cuvette solutions 
were reduced with a few grains of sodium dithionite, and the sample cuvette only 
was bubbled gently with 100% carbon monoxide (BOC, Polmadie, Scotland) for 
approximately 1 min. The spectrum was then re-scanned from 400 nm to 500 nm 
and the absorbance at 490 and 450 nm recorded.
2.1.3 Incubation of propofol with hepatic microsome preparations
All chemicals used for incubations were purchased from Sigma Chemical Co., 
Dorset, England unless stated otherwise. All solutions were stored at 0-4°C.
Since the activity of cyto P450 relies on the presence of NADPH, a continuing 
supply of this system, must be present throughout the incubation period (Gibson & 
Skett., 1994). The NADPH generating system used consisted of NADP+> 1 mM, 
isocitrate dehydrogenase (0.2 units/ml), trisodium isocitrate, 15 mM, nicotinamide, 
0.5M and MgCl2, 0.15M, made up to a final volume of 10 ml in Tris buffer, 0.1M, 
pH 7.4. MgCl2 and nicotinamide were prepared in water, from hexahydrate (Analar, 
Hopkin & Williams, Chadwell Heath, Essex) and niacinamide respectively. This
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NADPH generating system was prepared immediately before incubation and 1 ml 
was used in each tube.
Microsomes were diluted to a working protein concentration of 12 mg/ml in Tris 
buffer, 0.1M, pH 7.4 containing 20% glycerol (v:v), unless stated otherwise. In 
order to assess the degree of extra microsomal drug degradation and drug stability 
during the incubation process, control microsomes (inactivated) were prepared by 
heating aliquots (70-100°C) for 10 min.
2.1.3.1 Degradation of propofol by hepatic microsome preparations (rat & 
sheep)
Propofol was prepared from pure compound, (ICI Pharmaceuticals Co.), in dimethyl 
sulfoxide (DMSO) to a standard concentration of 500 pg/ml (2805 pM).
A pilot experiment was carried out to approximate the time course of propofol 
degradation by rat hepatic microsomes in order to select an appropriate incubation 
time for other studies. The incubation procedure was a modification of methods 
described previously by Fargetton et al. (1986); Galtier et al. (1986), for 
benzimidazole studies and by Baker et al. (1993), for propofol. All incubations were 
conducted aerobically at 37°C, in a shaking water bath (Grant Instruments Ltd, 
Cambridge) with a shaking speed of 120 cycles/min. The final incubation volume 
was 2 ml. Firstly, propofol, 28, 56, 84 and 140 pM in DMSO or DMSO (range 20- 
100 pi) and NADPH generating system (1 ml) were added to glass test tubes and 
made up to a final volume of 2 ml with appropriate volumes of Tris buffer (range 
400-480 pi). This mixture was incubated for 2 min and subsequently 500 pi of 
active or inactive microsomal protein was added and re incubated for 5, 10, 15, 20, 
30, 45 or 60 min. Microsomal activity was stopped by placing the test tubes in ice 
for 5 min. The contents of the test tubes were transferred to 5 ml neutral tubes 
(Sarstedt, Ltd. Leicester) and stored at -20°C until chromatography was performed, 
usually within one week of incubation. Seven rats (Sprague Dawley) were used in 
this study. Tissue from one animal was used for each incubation time. All tubes 
were prepared in duplicate.
Based on the results of this pilot experiment, the degradation of propofol by sheep 
and rat microsome preparations was studied using a 15 min incubation period.
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2.1.3.2 Interaction of propofol with cytochrome P450 and the influence of other 
drugs on propofol degradation
The effect of propofol on cyto P450 activity
The effect of propofol on cytochrome P450 activity was assayed by studying the 
rate of formation of formaldehyde from aminopyrine, a cytochrome P450 dependent 
N-demethylation process, in the presence and absence of various concentrations of 
propofol. A standard solution of aminopyrine, 25 mM, was prepared in water from 
4-dimethyl aminoantipyrine and the solution was stored in an amber bottle. Propofol 
standard solutions were prepared in DMSO at concentrations of 280 pM, 2.8 mM 
and 28 mM. The NADPH generating system was modified to include semicarbazide 
(MgCl2, 0.15M was replaced by MgCl2, 0.15M/semicarbazide, 0.1M), (see 2.1.3). 
Microsomal protein was diluted to a working concentration of 10 mg/ml in Tris 
buffer, 0.1M, pH 7.4 containing 20% glycerol (v:v).
The method used was described by Gibson and Skett (1994). Four hundred pi of the 
standard aminopyrine solution was placed into glass test tubes, (blank samples were 
prepared by replacing aminopyrine with 400 pi of distilled water). Propofol, 5.6, 56, 
280 or 561 pM (40 pi of the different standard solutions), DMSO (40 pi) or Tris 
buffer (40 pi) were then added to each respective tube. Subsequently, NADPH 
generating system (1 ml) and Tris buffer (60 pi) were added to give a total volume 
of 2 ml in each tube. The mixture was pre incubated for 2 min as described 
previously. The reaction was started by the addition of active or inactive 
microsomes (500 pi) and the mixture was then incubated for 15 min. Enzyme 
activity was stopped by placing the tubes on ice for 5 min and with the addition of 
zinc sulphate, 25% (500 pi). Protein was precipitated by the addition of a saturated 
solution of barium hydroxide (500 pi) and the tubes were maintained on ice for a 
further 5 min. The mixture was then centrifuged at 3000 g for 5 min. Subsequently, 
1 ml of the clear supernatant was removed into glass test tubes, mixed with 2 ml of 
Nash reagent, covered to prevent water loss and incubated at 60°C for 30 min to 
permit maximum colour development. The tubes were then cooled by placing them 
into ice for 5 min and the absorbance of each solution was read at 415 nm in a 
UV/Vis spectrophotometer. The concentration of formaldehyde in the sample tubes 
was calculated with the use of a standard curve.
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The standard curve for the assay of formaldehyde concentration was prepared by 
diluting 0, 0.2, 0.4, 0.6, 0.8 and 1.0 ml of a freshly prepared solution of 
formaldehyde, 0.7 mM, to 1 ml with distilled water. Nash reagent (2 ml) was added 
to each tube, and the tubes incubated and assayed as described above. Absorbance 
values were plotted against known concentrations of formaldehyde and a standard 
curve was constructed.
Extra cyto P450 degradation of propofol
In order to determine whether propofol was metabolised by hepatic enzymatic 
systems other than cyto P450, the activity of this enzymatic system was inhibited 
with 1-aminobenzotriazole (ABT; 12 mM), a suicide substrate for the cyto P450 
enzymatic system (Mugford et al, 1992). A standard solution of propofol (500 
pg/ml) was prepared as described previously (see 2.1.3.1) and a solution of ABT, 
240 mM, was prepared freshly in Tris buffer, 0.1M, pH 7.4.
Propofol, 28, 56, 84 or 140 pM in DMSO or DMSO (range 20-100 pi) was placed 
into glass test tubes. ABT, 12 mM (100 pi of 240 mM) was allocated to appropriate 
tubes. NADPH generating system (1 ml) and Tris buffer, to yield a final tube 
volume of 2 ml (range 300-480 pi), were then added to each tube and pre incubated 
for 2 min. Five hundred pi of active or inactive microsomes was allocated into 
appropriate tubes and the mixture incubated for a further 15 min as described in
2.1.3.1
The effect of other drugs on the degradation of propofol
Standard solutions of ketamine (200 pg/ml) and alfentanil (Janssen Pharmaceuticals 
Ltd), (100 pg/ml) were prepared in Tris buffer and standard solution of aminopyrine 
(25 mM) was prepared in water from 4-dimethyl aminoantipyrine.
For each drug-propofol interaction study, 28 tubes were used. These included 
propofol alone, propofol & DMSO, propofol & drug and propofol & inactive 
microsomes. Propofol 28, 56, 84 or 140 pM in DMSO or DMSO (range 20-100 pi) 
were placed into glass test tubes. Ketamine, 5 pg/ml (50 pi of 200 pg/ml), 
alfentanil, 200 ng/ml (4 pi of 100 pg/ml) or aminopyrine, 5 mM (400 pi of 25 mM) 
was placed in appropriate tubes. NADPH generating system (1 ml) and Tris buffer, 
to yield a final volume of 2 ml (range 0-480 pi) were then added to each tube and 
pre incubated for 2 min. Five hundred pi of active or inactive microsomes were 
allocated into appropriate tubes and the mixture incubated for 15 min as described 
in 2.1.3.1.
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2.1.4 Lung microsomes 
Preparation of lung microsomal specimens
Lung microsomes were prepared according to the method of Miles and colleagues,
(1993). Rats were killed by cervical dislocation, the thoracic and abdominal cavities 
opened and the lungs collected into ice cold Tris buffer, 0.1M, pH 7.4. Once the 
lungs were collected, all procedures were carried out at 0-4°C. The lungs were freed 
of connective tissue, blotted dry, weighed, placed into 4 volumes of ice cold Tris 
buffer, and finely sliced before homogenisation using a Teflon-glass Potter- 
Elvejhem homogeniser (6 complete passes with the pestle). The tissue homogenate 
was then subjected to differential centrifugations. Cell nuclei and debris were 
removed by centrifugation at 1000 g for 10 min. The mitochondrial fraction was 
slowly sedimented by two sequential centrifugations for 20 min each, at 10000 g 
and 15000 g and subsequently, the microsomal fraction was sedimented by 
centrifugation at 105000 g for 75 min. The cytosolic fraction was discarded and the 
microsomal pellet resuspended in 2 ml of Tris buffer, containing 20% glycerol (v:v), 
divided into aliquots (1 ml), immediately frozen in liquid nitrogen and stored at - 
80°C until used (within one week). Twenty pi of the resuspended microsomes was 
used for measurement of the protein concentration in the microsomal preparation. 
This was carried out as described previously (see 2.1.2).
Because of the high spectral interference of oxy- and deoxy-haemoglobin during the 
spectral measurement of cytochrome P450, the content of this enzymatic system in 
the lung microsomal preparations could not be measured.
The incubation of propofol with lung microsomes was performed as described 
previously, but, because of the small concentration of protein obtained from lung 
preparations, the concentration of protein in the incubation mixture was decreased 
to 400 pg. Tubes without microsomes were used to assess for extra microsomal 
degradation of propofol and drug stability during incubation. Propofol was used at 
tube concentrations of 5.6, 11, 28 and 56 pM. Briefly, propofol in DMSO or DMSO 
(range 4-40 pi), Tris buffer, to yield a final volume of 2 ml (range 760-796 pi) and 
NADPH generating system (1 ml) were pre incubated in glass test tubes for 2 min. 
Two hundred pi of active microsomes or Tris buffer, were then added to appropriate 
tubes and the incubation performed for 15 min as described previously (see 2.1.3.1).
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2.1.5 Propofol analysis
Propofol was assayed by high performance liquid chromatography (HPLC) with 
fluorescence detection
Standards and chemicals
All solutions were stored at 4°C. A stock solution of propofol (200 pg/ml), was 
prepared from pure compound (ICI Pharmaceuticals), using methanol (HPLC grade, 
Rathbum Chemicals Limited, Walkerbum) as solvent. This solution was used for all 
subsequent dilutions. Thymol was used as the internal standard. A stock solution 
(100 pg/ml) was prepared in methanol, from pure compound (Sigma Chemical Co. 
Ltd, Dorset England) and was further diluted to a working solution of 2 pg/ml. 
Tetramethylammonium hydroxide (TMAH, Sigma Chemical Co. Ltd, Dorset 
England) was used as a 7.5% solution in propan-2-ol (Analar, Rathbum Chemicals 
Ltd Walkerbum), which was prepared immediately prior to use. Phosphate buffer, 
0.1M, was prepared in distilled water from sodium dihydrogen orthophosphate 
(Analar, BDH Chemical Ltd, Poole England). The HPLC mobile phase consisted of 
a mixture of methanol:water:trifluoroacetic acid (TFA, Sigma Chemical Co Ltd, 
Dorset England) in a 70:30:0.1 (v:v:v:) ratio, respectively. The mobile phase was 
degassed for twenty minutes before use. A 2 pg/ml solution of propofol prepared 
from the stock solution in the HPLC mobile phase was used as an external standard 
for HPLC injection.
2.1.5.1 Extraction of propofol from spikes and samples
Spiked samples (hereafter referred to as spikes) were used to assess the percent 
recovery of propofol from microsomes for each assay, and to prepare a calibration 
curve in order to calculate the concentration of propofol in the sample tubes. Spikes 
were prepared as follows: microsomes (125 pi), Tris buffer (375 pi), were placed 
into six tubes (sj-s^) into which propofol or methanol only (25 pi), were added to 
yield final concentrations of 0, 0.5, 1.0, 2.0, 5.0 and 10 pg/ml. The spikes were then 
incubated between 5 and 60 min depending on the study, to parallel the same 
conditions as the samples.
Once the spikes were prepared, 0.5 ml of the sample was pipetted into appropriate 
tubes. Spikes and samples were then treated identically. 0.5 ml of phosphate buffer, 
0.1M, was pipetted into each tube, followed by 10 pi of thymol (2 pg/ml). The 
tubes were vortexed for 30 sec and cyclohexane (Analar, Rathbum Chemicals Ltd), 
(5 ml) was added. All tubes were then mixed for 30 min on a slow rotary mixer. 
Four ml of cyclohexane were removed from each tube, placed into fresh tubes 
containing TMAH, 50 pi, and evaporated to dryness under a stream of nitrogen, in a
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dri-block (Techne, Cambridge) at 50°C. When the samples were dried, the sides of 
the tube were washed down with cyclohexane (approximately 0.5 ml) and allowed 
to evaporate to dryness once again. Spikes and samples were reconstituted in at least 
200 pi of mobile phase, vortexed and sonicated for approximately 1 min and 200 pi 
of the reconstituted sample were used for chromatography.
2.1.5.2 Chromatography of propofol
The HPLC system (Gilson, Scotlab CoatBridge, Scotland) comprised an isocratic 
pump with a manometric module, connected to a sample injector. The samples were 
chromatographed on a 5 p ODS hypersil column, 120 mm x 6 mm (Shandon 
Scientific Ltd, Cheshire), connected to the sample injector and to a variable 
wavelength fluorescence spectrophotometer (Perkin Elmer Ltd., Beaconsfield, 
Buckinghamshire), The detector output was connected to a chart recorder 
(Rikadenki, Mitsui Electronics Ltd, Surrey).
The mobile phase was pumped through the column for at least 45 min at a flow rate 
of 1 ml/min before any injections were made. The excitation wavelength of the 
detector was set at 276 nm and the emission wavelength fixed at 310 nm. The chart 
recorder was set to 10 mV with a paper speed of 5 mm/min. When the baseline was 
stable, three or four external standards were injected before the injection of spikes 
and samples. The smallest peak height considered for calculations was twice the 
background noise and this was assumed to be the limit of quantification of the 
assay. One external standard was injected after the injection of two spikes or 
samples. The injection volume was 15 pi, in a 20 pi loop, and the analysis time was 
6 min. The chromatography always started and finished with the injection of an 
external standard.
2.1.5.3 Recovery of propofol from microsomes spikes and samples
The recovery of propofol from the spikes and samples was calculated by reference 
to the peak heights resulting from the injection of external standard solutions. The 
recoveries were then used to obtain a calibration curve, from which the 
concentration of the samples was obtained.
2.1.5.4 Intra- and inter-assay coefficient of variation
The reproducibility of the assays was assessed by determination of the coefficient of 
variation in replicated microsome spikes, which were analysed in a single day to 
obtain the intra-assay (within assay) coefficient of variation. The inter-assay or 
(between assay) coefficient of variation was obtained by reference to the assays 
performed on different days.
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2.1.5.5 Sensitivity of propofol chromatographic assay
The limit of quantification of the assay, corresponding to a peak height of one unit 
of chart paper (2.5 mm) was 20 ng/ml, and was twice the background noise of the 
baseline.
2.1.6 Result calculation and presentation
The overall velocity of propofol degradation was calculated as follows: 
concentration of propofol degraded (pmoles)/[time of incubation (min)* total 
protein in 2 ml (mg)]. The concentration of propofol degraded was obtained by 
subtracting the final propofol concentration (in 2 ml) from the initial propofol 
concentration (in 2 ml). This is considered to be overall velocity of the reaction 
because a large extent of substrate was used during the course of the assay (Segel, 
1975).
When a substantial fraction of the substrate is used during the assay (>5%), the Km 
and Vmax values obtained from the linear plots will be in error, if the initial 
substrate concentration is used. For these cases a linear plot can be used (even for 
90% use of the substrate), provided the arithmetic mean substrate ^([So] + [St]) 
(where t is the time of incubation), is used for the horizontal axis as shown by Lee 
& Wilson (1971). The substrate concentration used to obtain the graphs of the 
velocity plotted against substrate concentration and for the reciprocal of the velocity 
plotted against the reciprocal of the substrate (Lineweaver Burk plot) throughout the 
thesis were obtained by this way. The best fitting curve for the Lineweaver Burk 
plot was obtained by regression analysis (Cricket Graph, Computer associates Ltd. 
Manchester). The equation of the best-fitting regression curve was then used to 
obtain the maximal velocity (Vmax) and the Michaelis constant (Km).
2.1.7 Statistical analyses of the results
Results are presented as mean ± standard error of the mean (±sem). Stastitical 
analyses were performed using MINITAB stastitical software (CLE COM Ltd, 
Birmingham). The statistical tests used for each specific study are detailed below: 
Analysis of the effect of propofol on cyto P450 activity: a paired two sample
t-test.
Study of extra cyto P450 degradation of propofol: a two way analysis of 
variance was used intially, followed by a post hoc paired two sample t-test.
Effect of other drugs on the degradation of propofol: a two way analysis of 
variance was initially used, and a post hoc paired two sample t-test was carried out 
for the effect of aminopyrine on propofol degradation.
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Comparison of the degradation of propofol by sheep microsome preparations 
with degradation by rat microsome preparations: a two way analysis of variance was 
used.
Comparisons of Vmax & Km values for propofol in the presence or absence 
of other drugs: a two sample paired t-test was used.
For all tests, a P < 0.05 was considered significant.
2.2 P h a r m a c o k in e t ic s  a n d  p h a r m a c o d y n a m ic s  o f  
p ro p o fo l  in s h e e p
2.2.1 Animals and husbandry
Ten Scottish Blackface healthy female sheep, weighing between 21 and 29.5 kg and 
aged between 6 and 7 months were used in this study. They were housed in stables, 
and received hay and water ad libitum and concentrate pellets twice a day. All sheep 
underwent superficial surgery for the implantation of subcutaneous tissue cages. 
Two polypropylene tissue cages were implanted in the lumbar fossa of each side. 
The sheep were in lateral recumbency and were turned once during the surgery. The 
animals were divided randomly into 2 groups of five animals; Group 1 (Gl) was 
anaesthetised with propofol (sheep numbers 01 to 05), while group 2 (G2) received 
propofol and ketamine (sheep numbers 06 to 10). All animals were fasted for 24 
hours before each experiment, but left with access to water until just before the 
induction of anaesthesia.
2.2.2 Drug administration
Animals were premedicated intramuscularly with acepromazine maleate (ACP; C- 
Vet Ltd, Lancashire), 0.05 mg/kg and papaveretum (Ounopon, Roche, 
Hertfordshire), 0.4 mg/kg, mixed in the same syringe, 30 min before induction of 
anaesthesia. An intravenous catheter (Intraflon; Vygon) was placed in both the right 
and left jugular veins for animals in Gl. Two intravenous catheters were placed in 
the right jugular vein and one in the left jugular vein in all animals in G2. The 
catheters in the right jugular veins were used for drug administration while the one 
in the left jugular vein was used for drug sampling.
In Gl, anaesthesia was induced with propofol (Rapinovet; Mallinckrodt Veterinary, 
Cheshire), 4 mg/kg, i.v., and maintained with a variable infusion rate of propofol 
(0.3-0.5 mg/kg.min). In G2, anaesthesia was induced with propofol 3 mg/kg and 
ketamine (Vetalar; Parke Davis, Gwent), 1 mg/kg mixed together and given i.v.
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Anaesthesia was maintained in this group with infusion rates of propofol (0.2-0.3 
mg/kg.min) and ketamine (0.1-0.2 mg/kg.min). The decision to lower the infusion 
rate was based on the cardiovascular status of each individual animal and on clinical 
parameters such as the absence of palpebral reflexes, absence of skin twitches and 
movements to surgical manipulations. The induction drugs were injected over 60 
sec and the infusion started immediately after induction.
2.2.3 Sample collection
A control blood sample was taken before induction of anaesthesia. During the 
infusion period, samples were taken 2, 5, 10, 15, 30, 45 and 60 min after the 
beginning of the infusion. An extra sample was taken at the end of the infusion in 
animals in which the infusion lasted for more than 60 min. After the infusion was 
switched off, blood samples were collected 2, 5, 10, 15, 30, 45, 60, 90, 120, 180, 
240, 360, 540, 1320 and 1440 min. Samples (2 ml) were collected into glucose 
fluoride tubes (Sarstedt Ltd, Leicester, England), mixed well and kept at 4°C until 
drug assay, which was carried out within three weeks of sample collection.
2.2.4 Anaesthesia Monitoring
Pulse and respiratory rates were measured just before the induction of anaesthesia 
and were monitored throughout anaesthesia at 5 min intervals. Systolic arterial 
blood pressure was measured indirectly using a non invasive monitor (DINAMAP, 
Critikon Canada Inc.) also at 5 min intervals. The cuff for recording blood pressure 
was placed on a foreleg, just above the carpus. The time to recovery from 
anaesthesia was recorded from the time the infusion was switched off and was 
recorded as the time to endotracheal extubation, the time to sternal recumbency and 
the time to standing unaided.
2.2.5 Analysis of propofol in blood samples 
Standards and chemicals
All standards and chemicals were prepared as described previously for in vitro 
studies (see 2.1.5). The external standard solution for HPLC injection containing 
both propofol (300 ng/ml) and thymol (100 ng/ml) was prepared in the HPLC 
mobile phase.
2.2.5.1 Extraction of propofol from spikes and samples
The extraction procedure was similar in all aspects to that described for microsomes 
except that blood (0.5 ml) was used (see 2.1.5.1).
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2.2.5.2 Chromatography of propofol
The chromatography was performed as described previously for microsomes (See
2.1.5.2.).
2.2.5.3 Recovery of propofol from blood spikes and samples
Recovery of propofol from blood was calculated the same way as for microsomes 
(See 2.1.5.3).
2.2.5.6 Intra- and inter-assay coefficient of variation
The reproducibility of the assays was assessed by determination of the coefficient of 
variation in replicated blood spikes, which were analysed in a single day to obtain 
the intra-assay (within assay) coefficient of variation. The inter-assay or (between 
assay) coefficient of variation was obtained by reference to the assays performed on 
different days.
2.2.5.7 Sensitivity of propofol chromatographic assay
The limit of quantification of propofol in blood samples, corresponding to a peak 
height of one unit of chart paper (2.5 mm), was 10 ng/ml.
2.2.6 Pharmacokinetic analysis
The data used for pharmacokinetic analysis was obtained by analysing the changes 
in blood propofol concentration versus time, after a variable infusion rate of the 
drug which lasted for up to 75 min. All pharmacokinetic parameters were described 
using non-compartmental analyses of the data.
The mean residence time [MRT0bs (h)] is a quantitative estimate of the persistence 
of a drug in the body, or the time for 63.2% of a drug to be eliminated. It is 
calculated from AUMC0bs/AUC0bs, where AUMC0bs (pg.h2/ml) is the total area 
under the drug concentration time versus time or first moment curve, from time zero 
to last measured concentration, and AUC0bs (pg.h/ml) is the total area under the 
drug concentration versus time or zero moment curve, from time zero to the last 
measured concentration. The AUC0bs was calculated using the trapezoidal rule. 
The total body clearance, CLb, (ml/kg.min) is the sum of all clearance processes 
and is calculated from Dose/AUC0bs. The apparent volume of distribution at steady 
state concentration, Vdss, (L/kg) is calculated from Dose I.V. * 
(AUMC0bs/AUCobs) (Gibaldi & Perrier, 1975).
33
2.2.7 Statistical analyses
Statistical analyses were carried out using a Mann-Whitney test for pharmacokinetic 
data, an unpaired t-test for anaesthetic recovery times and a two way analysis of 
variance with replication for pulse rate, arterial blood pressure and respiratory rates. 
A post hoc unpaired t-test was carried out for respiratory rates. P<0.05 was 
considered significant. Results are expressed as means ± standard error of the mean 
(±sem).
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3. RESULTS
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3.1 D e g ra d a t io n  a n d  in te ra c t io n  o f  p ro p o fo l  w ith  
o th e r  d r u g s  in vitro
The protein and cytochrome P450 (cyto P450) concentrations of rat and sheep 
hepatic microsome preparations used in all studies are reported in appendices A1 to 
A5. The protein content of lung microsome preparations is reported in appendix A6. 
Due to spectrophotometric interference of haemoglobin during cyto P450, 
determination in microsomes prepared from lung tissue, it was not possible to 
measure the concentration of this enzymatic system in this tissue.
The mean percentage recovery of propofol microsome standards (range 0.5-10 
pg/ml) was 83.70 ± 0.82%. Four sets of standards (range 0.5-10 pg/ml) analysed 
during the same day showed a within a day coefficient of variation of 6.58 % and 
when the standards were analysed on different days the between assays coefficient 
of variation was 9.54 %.
3.1.1 Degradation of propofol by hepatic microsome preparations
When propofol was incubated with inactive microsomes there was no evidence that 
extra enzymatic degradation of the drug or drug instability during incubation 
accounted for any of the disappearance of propofol, since concentrations of 
propofol in boiled microsomes incubated under the same conditions as with active 
microsomes were in accordance with the initial concentrations used. No peaks were 
observed when hepatic microsomes were incubated with the vehicle (DMSO) alone.
Propofol was rapidly metabolised by hepatic microsomes with 3L% or more 
metabolised after 5 min of incubation. The extent of substrate degradation was 
variable depending on the initial concentration of the drug; 86.1, 70.5, 56.9 and 
36.6% of propofol was degraded after 5 min of incubation for initial propofol 
concentrations of 28, 56, 84 and 140 pM respectively (table 3.1.1). The velocity of 
degradation of propofol varied with different concentrations and decreased, for the 
same initial concentration, as the time of incubation, increased from 5 to 30 min 
(table 3.1.2). After 45 min of incubation the concentration of propofol remaining 
was variable, possibly due to enzyme instability or product inhibition (table 3.1.1). 
Consequently, data from these incubation times (45 & 60 min), were not used to 
estimate Vmax and Km. The graphical representation of the velocity (V) plotted 
against the substrate concentration (S) and the reciprocal of this plot (Lineweaver 
Burk plot) for 15 min incubation time is shown in figs 3.1.1 & 3.1.2 (substrate 
concentrations used to obtain these plots are shown in appendix A7).
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I.C.
Incubation time (min)
5 10 15 20 30 45 60
28 3.9 2.4 1.7 0.8 0.2 0.3 0.1
56 16.5 15.4 10.4 7.2 2.2 4.3 3.3
84 36.2 29.7 26.9 17.6 8.2 12.6 12.1
140 88.8 73.7 65.4 57.8 32.7 36.7 44.4
Table 3.1.1 - Initial propofol concentrations [(I.C) (pM)] and concentrations 
(pM), remaining after 5, 10, 15, 20, 30, 45 and 60 min of propofol incubation 
with rat hepatic microsomes. Each result is the mean of 2 determinations from 
one animal.
Incubation time
prop. 5 min 10 min 15min 20 min 30 min
28 0.29 0.15 0.10 0.08 0.06
56 0.47 0.24 0.18 0.15 0.11
84 0.57 0.32 0.23 0.20 0.15
140 0.61 0.40 0.30 0.24 0.21
Table 3.1.2 - The velocity (enzyme activity; pmoles/min.mg of protein) of the 
degradation of different concentrations of propofol (prop.; pM), when 
incubated for different times with hepatic microsome preparations. Each result 
is the mean of two determinations from one animal.
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Fig 3.1.1 - Velocity of propofol degradation plotted against propofol 
concentration for rat liver microsomes incubated for 15 min. Each point is 
the mean of two determinations from one rat.
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Fig 3.1.2- Lineweaver Burk plot for propofol incubated for 15 min with rat 
hepatic microsomes. Each point is the mean of two determinations from one 
rat.
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The maximal velocity (Vmax; pmoles/min/mg of protein) and the Michaelis 
constant (Km; pM) obtained were, 0.6/34.5; 0.53/37.6; 0.46/52.6; 0.41/58.8 and 
0.36/71.4 for 5, 10, 15. 20 and 30 min of incubation respectively. They were 
obtained by extrapolation from the Lineweaver Burk plots (Segel, 1975).
For all subsequent studies, the time of incubation was set at 15 min. This time was 
chosen in order to study drug interactions accurately although, the proportion of 
propofol degraded at this was relatively large (see discussion).
3.1.2 Effect of propofol on cytochrome P450 activity
The production of formaldehyde from the oxidative N-demethylation of 
aminopyrine was inhibited dose-dependently by propofol. There was no detectable 
production of formaldehyde when inactivated microsomes were substituted for 
active microsomes in the incubation. The concentration of formaldehyde produced 
in the presence of DMSO (vehicle), in the presence of increasing concentrations of 
propofol and in the absence of both is shown in table 3.1.3 and illustrated in Fig 
3.1.3. The presence of the vehicle alone reduced the production of formaldehyde by
18.5 ± 2.2% (n=6), but this difference was not statistically significant (P>0.05). 
Propofol decreased the mean production of formaldehyde by 21 ± 2.7 to 60.6 ± 
3.1%, dependent on the concentration of propofol present (table 3.1.4). The 
individual velocities of the production of formaldehyde are shown in table 3.1.5, the 
means varying from 0.09 ± 0.01 to 0.04 ± 0.01 pmoles/min.mg of protein, 
dependent on the concentration of propofol present. The concentration of 
formaldehyde produced in the presence of different concentrations of propofol were 
assessed statistically against the production of formaldehyde in the presence of 
DMSO only. Concentrations of propofol as small as 5.61 pM did not significantly 
alter the production of formaldehyde (P>0.05), but concentrations equal to or 
greater than 56 pM significantly affected the reaction, with PO.OOOl for 56 pM; 
P<0.001 for 280 pM and P<0.0005 for 560 pM. These data indicated that propofol 
has potential to inhibit the activity of cyto P450 enzymatic system.
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R1 R2 R3 R4 R5 R6 mean ±sem
control 0.14 0.27 0.34 0.15 0.23 0.23 0.23 0.03
dmso 0.11 0.22 0.3 0.11 0.20 0.19 0.19 0.03
5.6 0.11 0.23 0.28 0.10 0.19 0.18 0.18 0.03
56 0.08 0.18 0.25 0.07 0.15 0.14 0.15 0.03
280 0.06 0.15 0.18 0.06 0.10 0.08 0.11 0.02
561 0.05 0.12 0.17 0.05 0.10 0.07 0.09 0.02
Table 3.1.3 - Concentration of formaldehyde (mM) produced from the N- 
demethylation of aminopyrine by rat hepatic microsomes incubated in the 
absence (control) and in the presence of 5.6, 56, 280 and 561 pM of propofol 
in dmso (40 pi) and of dimethylsulfoxide alone (dmso; 40 pi). R1 and R4 were 
Wistar rats while R2, R3, R5 and R6 were Sprague Dawley rats. Each result is 
the mean of two determinations from one rat.
R1 R2 R3 R4 R5 R6 mean ±sem
dmso 21.4 18.5 11.8 26.7 13.1 17.4 18.5 2.2
5.6 21.4 14.8 17.7 33.3 17.4 21.7 21.0 2.7
56 42.9 33.3 26.5 33.3 34.8 39.1 34.9* 2.2
280 57.2 44.5 47.1 60.0 56.5 65.2 55.1* 3.2
561 64.3 55.6 50.0 66.7 56.5 69.6 60.4a 3.1
Table 3.1.4 - Percentages inhibition of the production of formaldehyde from 
the N-demethylation of aminopyrine by rat hepatic microsomes, in the presence 
of dimethylsulfoxide, (dmso, 40 pi) and of increasing concentrations (5.6, 56, 
280 and 561 pM) of propofol (40 pi) dissolved in dmso. Each result is the 
mean of two determinations from one rat. (*P<0.0001; »P<0.001; aP<0.0005, 
compared with dmso alone).
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R1 R2 R3 R4 R5 R6 mean ±sem
control 0.06 0.11 0.14 0.06 0.09 0.09 0.09 0.01
dmso 0.04 0.09 0.12 0.04 0.08 0.08 0.08 0.01
5.6 0.04 0.09 0.11 0.04 0.08 0.07 0.07 0.01
56 0.03 0.07 0.10 0.03 0.06 0.06 0.06 0.01
280 0.02 0.06 0.07 0.02 0.04 0.03 0.04 0.01
561 0.02 0.05 0.07 0.02 0.04 0.03 0.04 0.01
Table 3.1.5 - The velocity (pmoles/min.mg of protein) of the production of 
formaldehyde from the N-demethylation of aminopyrine by rat hepatic 
microsomes, incubated for 15 min, in the presence of dimethylsulfoxide (dmso) 
alone, of increasing concentrations of propofol in dmso (5.6, 56, 280 and 561 
pM) and in the absence of both (control). Each result is the mean of two 
determinations from one rat.
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Fig 3.1.3 -The concentration of formaldehyde produced from the 
N-demethylation of aminopyrine by rat hepatic microsomes in the presence of 
dimethylsulfoxide (dmso); 5.6, 56, 280 and 561 pM of propofol in dmso or in 
the absence of both (Control). Each point is the mean (+/-sem) of microsome 
preparations from six rats and each preparation was assayed in duplicate. 
*P<0.001; **P<0.0005; ***P<0.0001 (compared with dmso).
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3.1.3. Extra cytochrome P450 degradation of propofol
Inhibition of cyto P450 with 1-aminobenzontriazole (ABT) caused a significant 
(PO.OOOl) decrease in propofol degradation. The mean percentages inhibition of 
propofol degradation were 75.4, 57.2, 47 and 29.5% which were recorded for initial 
propofol concentrations of 28, 56, 84 and 140 pM respectively. Table 3.1.6 presents 
the concentration of propofol remaining after 15 min incubation, for the three 
different treatments (propofol alone, propofol with ABT and propofol with inactive 
microsomes). The effect of cyto P450 inhibition with ABT and the presence of 
inactive microsomes on propofol degradation is demonstrated in fig 3.1.4. The 
velocity of degradation of propofol was also significantly decreased in the presence 
of ABT (p<0.001). The mean velocities (pmoles/min.mg of protein) were 0.09 ± 
0.00; 0.13 ±0.01; 0.16 ± 0.02 and 0.18 ± 0.02 in the absence of ABT and 0.02 ± 
0.00; 0.02 ±0.01; 0.04 ± 0.00 and 0.04 ±0.01 in the presence of ABT for propofol 
concentrations of 28, 56, 84 and 140 pM, respectively, (n=6) (table 3.1.7).The 
velocity of propofol degradation plotted against substrate concentration for this 
inhibition is illustrated in fig 3.1.5. (concentrations of substrate used for this plot are 
in appendix A8).
During this assay, two different strains of rat were used, 3 Wistar rats (Rl, R3 and 
R4) and 3 Sprague Dawley rats (R2, R5 and R6). Microsomes from Sprague 
Dawley rats degraded propofol significantly (P<0.05) faster than those obtained 
from Wistar rats (table 3.1.6 & 3.1.7).
These data indicate that there is no extra enzymatic degradation of propofol or 
evidence of propofol instability when incubated with inactive microsomes. The lack 
of difference between initial concentrations of propofol and concentrations 
remaining after incubation with ABT indicates that propofol does not undergo extra 
cyto P450 metabolism.
3.1.4 The effect of other drugs on the degradation of propofol by 
rat hepatic microsomes (Sprague Dawley)
The concentration of propofol remaining after 15 min incubation with and without 
ketamine, alfentanil or aminopyrine are shown in tables 3.1.8, 3.1.9 & 3.1.10 and 
illustrated in figs 3.1.6, 3.1.7 & 3.1.8 respectively.
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I.C. R l R2 R3 R4 R5 R6 mean ±sem
28 8.2 3.2 8.3 7.1 1.9 3.5 5.4 1.1
56 26.5 17.9 64.6 28.9 13.3 17.8 28.2 7.7
84 50.4 39.2 57.4 50.8 31.1 36.3 44.2 4.1
140 98.2 88.6 114.4 96.8 80.1 85.3 93.9 5.0
28* 21.5 21.2 26.2 25.7 26.9 23.6 24.2 1.0
56* 47.1 48.2 56.8 52.7 50.7 45.9 50.2 1.6
84* 71.4 75.7 75.6 75.2 78.5 71.0 74.6 1.2
140* 133.6 130.8 141.7 131.7 126.5 120.7 130.8 2.9
28* 29 31.8 27.2 28.7 27.2 27.1 28.5 0.7
56* 58.2 62.5 60.8 57.4 58.5 53 58.4 1.3
84* 83.4 90.8 90.6 82.9 85.1 82.6 85.9 1.6
140* 136.4 143.4 139.9 139.8 146.9 140.7 141.4 2.6
Table 3.1.6 - Initial propofol concentrations (I.C.; pM) and concentrations 
(pM) remaining after incubation of rat hepatic microsomes for 15 min, with 
propofol only, propofol and 1-aminobenzontriazole (•) 12 mM, or propofol 
with inactivated microsomes (*). R l, R3 and R4 were Wistar rats, while R2, 
R5 and R6 were Sprague Dawley rats. Each result is the mean of two 
determinations from one rat.
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prop Rl R2 R3 R4 R5 R6 mean ±sem
28 0.08 0.1 0.08 0.08 0.10 0.10 0.09 0.00
56 0.12 0.15 0.08 0.11 0.17 0.15 0.13 0.01
84 0.13 0.18 0.11 0.13 0.21 0.19 0.16 0.02
140 0.17 0.20 0.10 0.17 0.24 0.22 0.18 0.02
to 00 • 0.03 0.03 0.01 0.01 0.001 0.02 0.02* 0.00
56* 0.04 0.03 0.00 0.01 0.02 0.04 0.02* 0.01
•00 0.05 0.03 0.03 0.04 0.02 0.05 0.04* 0.00
140* 0.03 0.04 0.00 0.03 0.05 0.09 0.04* 0.01
Table 3.1.7 - The velocity (enzyme activity; pmoles/min.mg of protein) of the 
degradation of propofol (prop. 28, 56, 84 and 140 pM), incubated with hepatic 
microsome preparations for 15 min, in the absence and in presence (•) of 1- 
aminobenzotriazole (ABT, 12 mM). Each result is the mean of two 
determinations from one rat. (*P<0.001).
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Fig. 3.1.4- Initial propofol concetrations (ic) and propofol concentrations remaining 
after incubation of rat hepatic microsome preparations with variable concentrations of 
propofol (p), propofol and 1-aminobenzotriazole (p/abt) and propofol in the presence 
of inactivated microsomes (bm). The incubation time was 15 min. The data is shown 
as the mean (+/-sem) of microsome preparations from six rats and each preparation 
was assayed in duplicate. *P<0.0001(p compared to p/abt).
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Fig 3.1.5- The velocity of propofol degradation plotted against propofol 
concentration for rat hepatic microsomes incubated with propofol alone (P) or with 
propofol and 1-aminobenzotriazole (P/ABT), for 15 min. Each point is the mean 
(+/-sem) of microsome preparations from six rats and each preparation was assayed 
in duplicate. *P<0.001(P compared to P/ABT).
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I.C. R l R2 R3 R4 R5 R6 mean ±sem
28 0.3 1.5 1.5 1.7 1.5 1.3 1.3 0.2
56 1.8 8 9.8 12.4 8.4 8.3 8.1 1.4
84 8.6 19.8 26.9 24.9 24.1 20.5 20.8 2.7
140 32.0 55.2 66.9 69.8 62.1 59.2 57.5 5.5
28* 0.5 1.7 1.7 1.9 2.2 1.8 1.6 0.2
56* 3.5 8.4 11.2 13.6 10.38 9.5 9.4 1.4
84* 10.1 20.9 26.3 28.2 25.2 22.2 22.1 2.6
140* 33.7 52.8 66.4 70.8 60.0 55.7 56.6 5.3
Table 3.1.8 - Initial propofol concentration (I.C.; pM) and propofol 
concentrations (pM) remaining after incubation of rat hepatic microsome 
preparations for 15 min, with propofol only or propofol and ketamine (*). Each 
result is the mean of two determinations from one rat.
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I.e . R l R2 R3 R4 R5 R6 mean ±sem
28 2.4 3.8 4.8 1.2 1.9 3.3 2.7 0.5
56 12.8 15.8 18.3 7.8 10.4 16.2 13.5 1.6
84 34.6 39.1 35.7 17.1 25.6 32.3 30.7 3.3
140 89.4 109.9 81.7 46.9 65.4 75.6 78.1 8.7
28* 2.4 3.2 5.0 1.3 2.2 3.5 2.9 0.5
56* 13.2 15.4 16.2 7.9 10.8 13.5 12.8 1.2
84* 33.8 40.2 34.2 17.1 22.9 30.5 29.8 3.4
140* 94.61 107.4 80.1 41.8 65.0 76.8 77.6 9.3
Table 3.1.9 - Initial propofol concentration (I.C.; pM) and propofol 
concentrations (pM) remaining after incubation of rat hepatic microsome 
preparations for 15 min, with propofol only or propofol and alfentanil (*). Each 
result is the mean of two determinations from one rat.
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I.C. R l R2 R3 R4 R5 R6 mean ±sem
28 1.6 1.6 1.6 2.0 1.5 1.1 1.6 0.1
56 11.3 10.9 9.8 12.7 10.1 7.4 10.4 0.7
84 25.9 34.6 21.7 27.9 25.8 16.9 25.5 2.4
140 68.2 81.6 57.6 83.7 64.6 45.3 66.8 5.9
28* 6.7 7.3 6.1 8.8 5.8 5.7 6.7 0.5
56* 19.6 22.7 18.2 25.4 15.1 14.7 19.3 1.7
84* 37.0 43.9 32.6 40 34.8 27.3 35.9 2.4
140* 78.1 89.9 78.8 88.1 74.0 58.1 77.8 4.7
Table 3.1.10 - Initial propofol concentration (I.C.; pM) and propofol 
concentrations (pM) remaining after incubation of rat hepatic microsome 
preparations for 15 min, with propofol only or propofol and aminopyrine (*). 
Each result is the mean of two determinations from one rat.
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Fig 3.1.6 - The concentration of propofol remaining after 15 min incubation of 
rat hepatic microsomes with propofol (28, 56, 84 and 140 pM) alone (P) or in 
the presence of ketamine, 5 |Lig/ml (P/Ket). Each point is the mean (+/-sem) of 
microsome preparations from six rats and each preparation was assayed in 
duplicate.
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Fig 3.1.7 - The concentration of propofol remaining after 15 min incubation of rat 
hepatic microsomes with propofol (28, 56, 84 and 140 }iM) alone (P) or in the 
presence of alfentanil, 200 ng/ml (P/Alf). Each point is the mean (+/-sem) of 
microsome preparations from six rats and each rat was assayed in duplicate.
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Fig 3.1.8 - The concentration of propofol remaining after 15 min incubation of rat 
hepatic microsomes with propofol (28, 56, 84 and 140 pM) alone (P), or in the presence 
of aminopyrine, 5 mM (P/Am). Each point is the mean (+/-sem) of microsome 
preparations from six rats and each preparation was assayed in duplicate. *P<0.005; 
**P<0.001; ***P<0.0001 (comparison made between P and P/Am data at each 
concentration.
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Ketamine (5 |ig/ml) and alfentanil (200 ng/ml) did not significantly alter the cyto 
P450 rate of degradation of propofol (P>0.05), but the rate of propofol (28, 56, 84 
& 140 pM), degradation was significantly decreased by aminopyrine, 5 mM 
(P<0.001). The mean velocities decreased from a range 0.11 ± 0.00 & 0.29 ± 0.02 to 
a range 0.09 ± 0.00 & 0.25 ± 0.02. Post hoc "t" test analysis showed significance 
values of P<0.0001 for 28 pM, P<0.001 for 56 pM, PO.OOOl for 84 pM and 
P<0.005 for 140 pM of propofol. The mean velocities (pmoles/min.mg of protein) 
of propofol degradation for concentrations of 28, 56, 84 and 140 pM respectively 
were 0.11 ± 0.01, 0.19 ± 0.01, 0.25 ± 0.01 and 0.33 ± 0.02 in the absence of, and 
0.10 ± 0.00, 0.19 ± 0.01, 0.25 ± 0.01 and 0.33 ± 0.02 pmoles/min/mg protein in the 
presence of ketamine (table 3.1.11). The mean velocities of propofol degradation in 
the absence and presence of alfentanil were respectively 0.10 ± 0.00, 0.17 ± 0.01, 
0.21 ± 0.01, 0.25 ± 0.03 and 0.10 ± 0.00, 0.17 ± 0.00, 0.20 ± 0.01, 0.22 ± 0.02 
pmoles/min/mg protein (table 3.1.12). The mean velocities of propofol degradation 
in absence and presence of aminopyrine were 0.11 ± 0.00, 0.18 ± 0.01, 0.23 ± 0.01, 
0.29 ± 0.02 and 0.09 ± 0.00, 0.14 ± 0.01, 0.20 ± 0.01, 0.25 ± 0.02 pmoles/min/mg 
protein, (table 3.1.13). Figs 3.1.9 to 3.1.11 show the velocities of propofol 
degradation plotted against substrate concentrations. The Lineweaver Burk plots for 
the three drugs are shown in figs 3.1.12 to 3.1.14 (substrate concentrations used for 
these plots are presented in appendix A9, A10 and All).The mean maximal 
velocities (Vmax, pmoles/min.mig protein) were respectively, 0.52 ± 0.08 & 0.56 ± 
0.06 for propofol and propofol/ketamine; 0.43 ± 0.04 & 0.39 ± 0.03 for propofol 
and propofol/alfentanil and 0.42 ± 0.04 & 0.43 ± 0.06 for propofol and 
propofol/aminopyrine. The mean Michaelis constants (Km, pM) were respectively 
46.5 ± 2.5 & 53.2 ± 3.2 for propofol and propofol/ketamine (table 3.1.14); 48.9 ± 
2.2 & 48.7 ± 4.4 for propofol and propofol/alfentanil (table 3.1.15) and 43.6 ± 5.0 
& 66.2 ± 7.6 for propofol and propofol/aminopyrine (table 3.1.16). The Vmax for 
propofol incubated alone was not significantly altered from the Vmax obtained for 
incubations of propofol with the three different drugs (P>0.05), however, the Km 
was significantly increased from 43.6 pM to 66.2 pM when propofol was incubated 
without and with aminopyrine respectively (P<0.05). These data indicate that 
aminopyrine is acting as a competitive inhibitor of propofol metabolism.
)
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prop. R l R2 R3 R4 R5 R6 mean ±sem
28 0.11 0.11 0.11 0.10 0.11 0.11 0.11 0.01
56 0.22 0.19 0.18 0.17 0.19 0.19 0.19 0.01
84 0.30 0.25 0.23 0.23 0.24 0.25 0.25 0.01
140 0.43 0.34 0.29 0.28 0.31 0.32 0.33 0.02
28* 0.11 0.10 0.10 0.10 0.10 0.10 0.10 0.00
56* 0.21 0.19 0.18 0.17 0.19 0.18 0.19 0.01
84* 0.29 0.25 0.23 0.22 0.23 0.25 0.25 0.01
140* 0.42 0.35 0.29 0.28 0.32 0.33 0.33 0.02
Table 3.1.11 - The velocity (pmoles/min.mg of protein) of the degradation of 
propofol (prop 28, 56, 84 and 140 pM), incubated with rat hepatic microsome 
preparations for 15 min, in the absence and in the presence (*) of ketamine (5 
pg/ml). Each result is the mean of two determinations from one rat.
prop. R l R2 R3 R4 R5 R6 mean ±sem
28 0.10 0.10 0.09 0.11 0.10 0.10 0.10 0.00
56 0.17 0.16 0.15 0.19 0.18 0.16 0.17 0.01
84 0.20 0.18 0.19 0.27 0.23 0.21 0.21 0.01
140 0.20 0.12 0.23 0.37 0.30 0.26 0.25 0.03
28* 0.10 0.10 0.09 0.11 0.10 0.25 0.10 0.00
56* 0.17 0.16 0.16 0.19 0.18 0.21 0.17 0.00
84* 0.20 0.17 0.20 0.20 0.24 0.17 0.20 0.01
140* 0.18 0.13 0.24 0.24 0.30 0.10 0.22 0.02
Table 3.1.12 - The velocity (pmoles/min.mg of protein) of the degradation of 
propofol (prop 28, 56, 84 and 140 pM), incubated with rat hepatic microsome 
preparations for 15 min, in the absence and in the presence (*) alfentanil (200 
ng/ml). Each result is the mean of two determinations from one rat.
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prop. R l R2 R3 R4 R5 R6 mean ±sem
28 0.10 0.10 0.11 0.10 0.11 0.11 0.11 0.00
56 0.18 0.18 0.18 0.17 0.18 0.19 0.18 0.00
84 0.23 0.20 0.25 0.20 0.23 0.27 0.23 0.01
140 0.29 0.23 0.33 0.22 0.30 0.38 0.29 0.02
28* 0.08 0.08 0.09 0.08 0.09 0.09 0.09 0.00
56* 0.14 0.13 0.15 0.12 0.16 0.16 0.14 0.01
84* 0.19 0.16 0.20 0.18 0.20 0.24 0.20 0.01
140* 0.25 0.20 0.24 0.21 0.26 0.33 0.25 0.02
Table 3.1.13 - The velocity (pmoles/min.mg of protein) of the degradation of 
propofol (prop. 28, 56, 84 and 140 pM), incubated with rat hepatic microsome 
preparations for 15 min, in the absence and in the presence (*) of aminopyrine 
(5 mM). Each result is the mean of two determinations from one rat.
propofol propofol/ketamine
Vmax Km Vmax Km
Rl 0.89 55.0 0.78 65
R2 0.50 50.9 0.61 50
R3 0.39 36.9 0.44 49
R4 0.41 45.0 0.40 43
R5 0.44 43.6 0.51 56
R6 0.47 47.4 0.63 56
mean 0.52 46.5 0.56 53.2
±sem 0.08 2.5 0.06 3.2
Table 3.1.14- Maximal velocity (Vmax; pmoles/min.mg protein) and Michaelis 
constant (Km; pM) for the degradation of propofol by rat hepatic microsome 
preparations incubated for 15 min with and without ketamine. Each result is the 
mean of two determinations from one rat.
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propofol propofol/alfentanil
Vmax Km Vmax Km
Rl 0.44 45 0.44 56.3
R2 0.32 40 0.29 33.3
R3 0.37 51 0.42 60.8
R4 0.58 53 0.31 38.0
R5 0.46 51 0.48 53.8
R6 0.41 51 0.41 49.9
mean 0.43 48.9 0.39 48.7
±sem 0.04 2.2 0.03 4.4
Table 3.1.15- Maximal velocity (Vmax; pmoles/min.mg protein) and Michaelis 
constant (Km; pM) for the degradation of propofol by rat hepatic microsome 
preparations incubated for 15 min with and without alfentanil. Each result is 
the mean of two determinations from one rat.
propofol propofol/aminopyrine
Vmax Km Vmax Km
R l 0.44 49.1 0.49 85.2
R2 0.32 31.4 0.30 45.9
R3 0.47 47.0 0.41 58.2
R4 0.30 32.0 0.27 48.8
R5 0.40 38.5 0.47 69.1
R6 0.59 63.7 0.65 90
mean 0.42 43.6 0.43 66.2*
±sem 0.04 5.0 0.06 7.6
Table 3.1.16- Maximal velocity (Vmax; pmoles/min.mg protein) and Michaelis 
constant (Km; pM) for the degradation of propofol by rat hepatic microsome 
preparations incubated for 15 min with and without aminopyrine. (*P<0.05). 
Each result is the mean of two determinations from one rat.
58
0 .5 - i
□ P
♦ P/K
Propofol concentration (pM)
Fig 3.1.9 -The velocity of propofol degradation plotted against propofol 
concentrations for rat hepatic microsomes incubated for 15 min with propofol 
alone (P) or with propofol and ketamine, 5 Jig/ml, (P/K). Each point is the 
mean (+/-sem) of microsome preparations from six rats and each preparation 
was assayed in duplicate.
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Fig 3.1.10 -The velocity of propofol degradation plotted against propofol 
concentrations for rat hepatic microsomes incubated for 15 min with propofol 
alone (P) or with propofol and alfentanil, 200 ng/ml (P/AF). Each point is the 
mean (+/-sem) of microsome preparations from six rats and each preparation 
was assayed in duplicate.
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Fig 3.1.11 -The velocity of propofol degradation plotted against propofol 
concentrations for rat hepatic microsomes incubated for 15 min with propofol 
alone (P) or with propofol and aminopyrine, 12 mM, (P/Am). Each point is the 
mean (+/-sem) of microsome preparations from six rats and each preparation 
was assayed in duplicate.
61
□ p
♦  P/Ket
K/i
' oI
£aa,
W>
B
.B
B
o
13
12
9
6
3
0
0.080 0.02 0.04 0.06
1/Propofol concentration (pM-1)
Fig 3.1.12 -Lineweaver Burk plot for propofol incubated for 15 min with rat 
hepatic microsomes in the absence (P) or in the presence of ketamine (P/Ket). 
Each point is the mean of microsome preparations from six rats and each 
preparation was assayed in duplicate.
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Fig 3.1.13 -Lineweaver Burk plot for propofol incubated for 15 min with rat 
hepatic microsomes in the absence (P) or in the presence of alfentanil (P/Alf). 
Each point is the mean of microsome preparations from six rats and each 
preparation was assayed in duplicate.
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Fig 3.1.14 -Lineweaver Burk plot for propofol incubated for 15 min with rat 
hepatic microsomes in the absence (P) or in the presence of aminopyrine 
(P/Am). Each point is the mean of microsome preparations from six rats and 
each preparation was assayed in duplicate.
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3.1.5 Degradation of propofol by sheep hepatic microsome 
preparations (a comparison with rat)
There were no statistically significant differences for the degradation of propofol by 
sheep hepatic microsomes when compared to rat hepatic microsomes (Sprague 
Dawley) at any drug concentration (P>0.05). Table 3.1.17 shows the concentrations 
of propofol remaining after incubation for 15 min, for both species. The mean 
velocities of propofol degradation for concentrations of 28, 56, 84 and 140 pM were 
0.11 ± 0.00, 0.18 ± 0.01, 0.23 ± 0.02 and 0.27 ± 0.03 pmoles/min.mg protein for 
sheep and 0.10 ± 0.00, 0.17 ± 0.01, 0.21 ± 0.01 and 0.25 ± 0.03 pmoles/min.mg 
protein for rat, respectively (table 3.1.18). The graphical representation of the 
velocity of propofol degradation plotted against substrate concentration and the 
Lineweaver Burk plot are illustrated in figs 3.1.15 and 3.1.16 respectively, 
(substrate concentrations used for these graphical representations are in appendix 
A12). The mean maximal velocities (Vmax; pmoles/min.mg protein) were 0.43 ± 
0.06 for sheep and 0.43 ± 0.04 for rat, and the mean Michaelis constant (Km; pM) 
42.0 ±7.1 for sheep and 48.9 ± 2.2 for rat (table 3.1.19). There were no statistically 
significant differences in the Vmax and Km between the two species.
3.1.6 Degradation of propofol by lung microsome preparations
The degradation of propofol (5.6, 11, 28 & 56 pM) by lung microsome preparations 
(400 pg of protein), obtained from Sprague Dawley rat was evident after 15 min 
incubation of these preparations with propofol. The mean velocities were 0.23 ± 
0.01, 0.36 ± 0.02, 0.48 ± 0.08 and 0.56 ± 0.17 pmoles/min.mg of protein for 
propofol concentrations of 5.6, 11, 28 and 56 pM respectively (table 3.1.20). The 
concentration of propofol remaining after 15 min incubation with and without 
microsome preparations are presented in table 3.1.21. There was no evidence of 
drug instability or extra enzymatic degradation when propofol was incubated 
without microsome preparations. The graphical representation of the velocity 
plotted against substrate concentration and the Lineweaver Burk plot are illustrated 
in figs 3.1.17 and 3.1.18 respectively (substrate concentration used for these plots 
are in appendix A13). The mean maximal velocity (Vmax) and the mean Michaelis 
constant (Km) obtained by extrapolation from the Lineweaver Burk plot were 0.93 
± 0.28 pmoles/min/mg of protein and 13.7 ± 4.8 pM respectively (table 3.1.22). 
These data indicate that lung tissue can degrade propofol in vitro.
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I.e. R1 R2 R3 R4 R5 R6 mean ±sem
28 4.8 0.6 1.1 0.4 0.1 ND 1.4 0.9
56 27.0 10.3 9.8 7.5 3.3 0.8 9.8 3.8
84 52.0 25.3 26.7 22.4 14.9 11.7 25.5 5.8
140 109.0 72.4 78.0 63.2 58.0 57.2 73.0 7.9
28* 2.4 3.8 4.8 1.2 1.9 3.3 2.7 0.5
56* 12.8 15.8 18.3 7.8 10.4 16.2 13.5 1.6
84* 34.6 39.1 35.7 17.1 25.6 32.3 30.7 3.3
140* 89.4 109.9 81.7 46.9 65.4 75.6 78.1 8.7
Table 3.1.17 - Initial propofol concentration (I.C.; pM) and propofol 
concentrations (pM) remaining after incubation of sheep and rat (*) hepatic 
microsome preparations for 15 min with propofol. Each result is the mean of 
two determinations from one animal.
prop. R1 R2 R3 R4 R5 R6 mean ±sem
28 0.09 0.11 0.11 0.11 0.11 0.11 0.11 0.00
56 0.12 0.18 0.18 0.19 0.21 0.22 0.18 0.01
84 0.13 0.23 0.23 0.24 0.27 0.29 0.23 0.02
140 0.12 0.27 0.25 0.31 0.33 0.33 0.27 0.03
28* 0.10 0.10 0.09 0.11 0.10 0.10 0.10 0.00
56* 0.17 0.16 0.15 0.19 0.18 0.16 0.17 0.01
84* 0.20 0.18 0.19 0.27 0.23 0.21 0.21 0.01
140* 0.20 0.12 0.23 0.37 0.30 0.26 0.25 0.03
Table 3.1.18 - The velocity (pmoles/min.mg of protein) of the degradation of 
propofol (prop. 28, 56, 84 and 140 pM), incubated with sheep and rat (*) 
hepatic microsome preparations for 15 min. Each result is the mean of two 
determinations from one animal.
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Sheep Rat
Vmax Km Vmax Km
A1 0.26 20 0.44 45
A2 0.37 33.8 0.32 40
A3 0.35 30.6 0.37 51
A4 0.44 43.7 0.58 53
A5 0.56 58.2 0.46 51
A6 0.62 65.8 0.41 51
mean 0.43 42.0 0.43 48.9
±sem 0.06 7.1 0.04 2.2
Table 3.1.19 - Maximal velocity (Vmax; pmoles/min.mg protein) and 
Michaelis constant (Km; pM) for the degradation of propofol by sheep and rat 
hepatic microsome preparations incubated for 15 min. Each result is the mean 
of two determinations from one animal.
prop. R1 R2 R3 R4 R5 mean ±sem
5.6 0.23 0.19 0.21 0.27 0.26 0.23 0.01
11 0.34 0.30 0.34 0.44 0.39 0.36 0.02
28 0.30 0.36 0.43 0.71 0.60 0.48 0.08
56 0.09 0.46 0.37 1.07 0.82 0.56 0.17
Table 3.1.20 - The velocity (pmoles/min.mg of protein) of the degradation of 
propofol (prop. 5.6, 11, 28 and 56 pM), incubated with rat lung microsome 
preparations for 15 min. Each result is the mean of two determinations from 
one rat.
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I.e. R1 R2 R3 R4 R5 mean ±sem
5.6 1.7 2.4 2.1 1.0 1.2 1.7 0.3
11 5.4 6.2 5.6 3.9 4.6 5.1 0.4
28 22.9 22.0 20.9 16.0 17.9 19.9 1.3
56 54.6 48.3 49.9 38.1 42.3 46.6 2.9
5.6* 5.2 6.4 5.4 4.9 5.4 5.5 0.2
11* 10.0 12.0 10.9 12.5 10.0 11.1 0.5
28* 30.0 29.9 27.0 27.8 28.6 28.7 0.6
56* 56.8 54.2 57.4 55.4 57.0 56.2 0.6
Table 3.1.21 - Initial propofol concentration (I.C.; pM) and propofol 
concentrations (pM) remaining after incubation of propofol with and without 
(*) rat lung microsome preparations for 15 min. Each result is the mean of two 
determinations from one rat.
R1 R2 R3 R4 R5 mean ±sem
Vmax 0.39 0.63 0.53 1.90 1.18 0.93 0.28
Km 2.9 11.2 6.3 30.2 17.9 13.7 4.8
Table 3.1.22 - Maximal velocity (Vmax; pmoles/min.mg protein) and 
Michaelis constant (Km; pM) for the degradation of propofol by rat lung 
microsome preparations incubated for 15 min. Each result is the mean of two 
determinations from one rat.
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Fig 3.1.15 -The velocity of propofol degradation plotted against propofol 
concentrations for sheep and rat hepatic microsomes incubated for 15 min. Each 
point is the mean (+/-sem) of microsome preparations from six animals and each 
preparation was assayed in duplicate.
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Fig 3.1.16 -Lineweaver Burk plot for propofol incubated for 15 min with sheep 
and rat hepatic microsomes. Each point is the mean (+/-sem) of microsome 
preparations from six rats and each preparation was assayed in duplicate.
70
1.5 -i
O 1 .2 -VhCl<
00a
d
0 .9 -
c«
0
1^
 0 .6 -
• ^oo
<D>
0 .3 -
355 15 20 25 300 10
Propofol concentration (pM)
Fig 3.1.17 -The velocity of propofol degradation plotted against propofol 
concentrations for rat lung microsomes incubated for 15 min. Each point is the 
mean (+/-sem) of microsome preparations from five rats and each preparation 
was assayed in duplicate.
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Fig 3.1.18 -Lineweaver Burk plot for propofol incubated for 15 min with rat 
lung microsomes. Each point is the mean of microsome preparations from five 
rats and each preparation was assayed in duplicate.
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3.2 P h a r m a c o k in e t ic s  a n d  p h a r m a c o d y n a m ic s  o f  
p ro p o fo l  in s h e e p
There were no statistically significant differences between the two groups in age, 
and body weight. All animals were female sheep, 7 months old with a mean weight 
of 26.9 ±1.4 (range 22-29.5) and 25.9 ± 1.5 (range 21-29.5) for group 1 (Gl) and 
group 2 (G2) respectively (table 3.2.1). The sheep were undergoing superficial 
surgery for implantation of subcutaneous tissue cages.
The mean percentage recovery of propofol blood standards (range 0.5-10 pg/ml) 
was 79.88 ± 0.87%. Four sets of standards (range 0.5-10 pg/ml) analysed during the 
same day showed a within a day coefficient of variation of 8.54 % and when the 
standards were analysed on different days the between assays coefficient of 
variation was 12.31 %.
Induction of anaesthesia was smooth in all animals in both Gl (propofol alone) and 
G2 (propofol and ketamine).
Endotracheal intubation was easily achieved in four animals in Gl, but failed at the 
first attempt in one animal (05), because anaesthesia was insufficiently deep. 
Endotracheal intubation in this animal was only possible after ten min of propofol 
infusion. In G2, intubation was achieved at first attempt in all animals, but in one 
animal (07) it was difficult.
Two sheep in Gl (02 and 04) had a propofol infusion longer than one hour (75 and 
69 min respectively). The mean duration of propofol infusion for this group was 
64.8 ±3.1 min (range 60-75 min) and the mean surgical period was 52.5±4.3 (range 
42-63) with a mean time to the first skin incision of 10.9 min after induction of 
anaesthesia. In all animals in G2 the infusion period was 60 min. The mean duration 
of surgery for G2 was 49±0.6 min (range 48-51) and the mean time to skin incision 
was 11.0 min after induction of anaesthesia (tables 3.2.2a & 3.2.2b).
The initial infusion rate of propofol for Gl was 0.5 mg/kg/min and this was 
decreased twice to 0.4 and 0.3 mg/kg/min respectively (tables 3.2.3a, b, c). In G2, 
which received propofol and ketamine the infusion rate was decreased once. The 
first infusion rates were 0.3 mg/kg/min of propofol and 0.2 mg/kg/min of ketamine. 
These were later decreased to 0.2 mg/kg/min and 0.1 mg/kg/min for propofol and 
ketamine respectively (tables 3.2.4a, b). The decision to alter the infusion rate was 
based on the cardiovascular status of each animal during the infusion and clinical
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Gl G2
sheep n° 01 02 03 04 05 06 07 08 09 10
WT (kg) 29 22 28 26 29.5 29.5 28 26 21 25
mean WT 26.9 25.9
±sem 1.4 1.4
Table 3.2.1 - Body weight (WT) for animals in G l (01-05) which received 
propofol alone and animals in G2 (06-10) which received propofol and 
ketamine, for the induction and maintenance of anaesthesia.
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sheep number infusion time 
(min)
surgical time 
(min)
01 60 42.5
02 75 63
03 60 45
04 69 62
05 60 50
mean 64.8 52.5
±sem 3.1 4.3
Table 3.2.2a
sheep number infusion time 
(min)
surgical time 
(min)
06 60 48
07 60 50
08 60 49
09 60 51
10 60 48
mean 60 49.2
±sem 0 0.6
Table 3.2.2b
Tables 3.2.2a,b - Infusion time and surgery duration for animals in G l (3.2.2a) 
which received only propofol and for those in G2 (3.2.2b) which received 
propofol and ketamine for induction and maintenance of anaesthesia.
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Initial rate - 0.5 mg/kg/min
sheep n° period total dose
01 0-30 435
02 0-35 385
03 0-10 140
04 0-20 260
05 0-32 472
Table 3.2.3a 
First alteration - 0.4 mg/kg/min
sheep n° period total dose
01 30-45 174
02 35-45 88
03 10-20 112
04 20-30 104
05 32-60 330
Table 3.2.3b
Second alteration - 0.3 mg/kg/min
sheep n° period total dose
01 45-60 130
02 45-75 198
03 20-60 336
04 30-69 304
05 - -
Table 3.2.3c
Tables 3.2.3a, b, c - Period (min) for each infusion rate applied (a: the initial 
infusion rate; b: the first alteration; c: the second alteration) and the total dose 
of propofol (mg) received during each period for animals in Gl which were 
anaesthetised with propofol. Time zero (0) is the time the infusion started, 
which was immediately after induction of anaesthesia.
76
Initial rate: - propofol - 0.3 mg/kg/min 
- ketamine - 0.2 mg/kg/min
sheep n° period
total dose
P k
06 0-18 159 106
07 0-31 260 174
08 0-31 242 161
09 0-30 189 126
10 0-30 225 150
41-60 142 95
Table 3.2.4a
First alteration: - propofol - 0.2 mg/kg/min 
- ketamine - 0.1 mg/kg/min
sheep n° period
total dose
P k
06 18-60 248 124
07 31-60 162 81
08 31-60 150 75
09 30-60 126 63
10 30-41 45 22
Table 3.2.4b
Tables 3.2.4a, b - Period (min) for each infusion rate applied (a: initial infusion 
rate; b: first alteration) and the total dose (mg) of propofol (p) and ketamine (k) 
received during each period, for animals in G2 which were anaesthetised with 
propofol and ketamine. Time zero (0) is the time the infusion started, which 
was immediately after induction of anaesthesia.
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assessment of the depth of anaesthesia. Consequently, the time of alteration varied 
between animals.
All animals in Gl and G2 were in a light plane of surgical anaesthesia during the 
infusion period. Intermittent skin twitching was present in two animals in Gl (35 
and 40 min after induction of anaesthesia), when the second surgical area was being 
clipped and this lasted 2 and 3 min respectively. One animal in G2 reacted to skin 
touch but not to skin incision, 35 min after induction. No purposeful movements 
were seen and the degree of analgesia appeared to be satisfactory.
The mean total dose (induction + infusion) of propofol received by animals in Gl 
was 801 ±42 mg of which 694 ± 23 mg was given during the infusion period. G2 
animals received a mean dose of propofol of 469.6 ± 23.2 mg of which 389.9 ± 19.4 
mg was given during the infusion and a mean dose of ketamine of 267.3±15.3 mg, 
of which 235.5± 13.4 was given during infusion (table 3.2.5a, b).
Recovery from anaesthesia was rapid and without excitement in all animals in both 
groups. The mean time to endotracheal extubation was 2.8 ± 0.4 and 5.3 ± 0.9 min, 
to sternal recumbency, 6.3 ±1.2 and 11.2 ± 1.7 min and to standing unaided, 10.9 ±
1.6 and 15.1 ± 2.2 min after infusion was switched off, for Gl and G2 respectively 
(tables 3.2.6a, b). There was a significant difference between the time to 
endotracheal extubation and sternal recumbency between the two groups (P<0.05).
Pulse rate, arterial blood pressure and respiratory rate were well maintained 
throughout the infusion period. In Gl, the mean pulse rate fell from 105 ± 15 
beats/min at 5 min to 95 ± 9 beats/min at 45 min. The mean systolic arterial blood 
pressure fell from 114 ± 10 mm Hg at 5 min to 98 ± 3 mm Hg at 30 min and the 
mean respiratory rate varied between 16 ± 1 and 19 ± 7 breaths/min during the 
infusion period. For animals in G2, the mean pulse rate varied between 102 ± 12 
and 107 ± 12 beats/min throughout anaesthesia. The mean systolic arterial blood 
pressure fell from 127 ± 17 mm Hg at 5 min to 96 ± 7 mm Hg at 30 min. The mean 
respiratory rates for this group were higher than for Gl at all time points throughout 
anaesthesia and ranged from 26 ± 3 to 45 ± 9 breaths/min (figs 3.2.1, 3.2.2 and 
3.2.3 respectively). One animal in Gl (02) and two animals in G2 (08; 09) were 
apnoeic post induction for 7, 2 and 3 min respectively. These animals were 
ventilated manually with 100% oxygen until spontaneous breathing resumed.
For animals in Gl, the mean blood propofol concentration at the time of skin 
incision was 4.9 ± 1.2 pg/ml (range 2.98-7.10). The maximum individual 
concentration of propofol in blood was achieved between 5 and 30 min after the 
beginning of the infusion and was between 4.8 and 10.3 pg/ml. At the time the
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sheep n° ind (mg) inf (mg) total (mg)
01 116 739.5 855.5
02 88 671 759
03 112 588 700
04 104 668.2 772.2
05 118 802.4 920.4
mean 107.6 693.8 801.4
±sem 5.5 36.2 38.7
Table 3.2.5
ind (mg) inf (mg) total (mg)
sheep n° P k P k P k
06 88.5 59 407.1 230.1 495.6 289.1
07 84 38 422.8 254.8 506.8 282.8
08 78 26 392 236 470 262
09 63 21 315 189 378 210
10 75 25 412.5 267.5 487.5 292.5
mean 77.7 31.8 389.9 235.5 467.6 267.3
±sem 4.4 6.9 19.4 13.4 31.8 15.3
Table 3.2.5b
Table 3.2.5a, b - Induction dose (ind), infusion dose (inf) and total dose (total) 
of propofol (p) and ketamine (k), received by animals in G l (3.2.5a) 
anaesthetised with propofol alone and by animals in G2 (3.2.5b) anaesthetised 
with propofol and ketamine.
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sheep
number
time to 
endotracheal 
extubation
time to 
sternal 
recumbency
time to 
standing 
unaided
01 4 10.5 12.5
02 2 5 11
03 3 6 15
04 3 7 11
05 2 3 5
mean 2.8 6.3 10.9
±sem 0.4 1.2 1.6
Table 3.2.6a
sheep
number
time to 
endotracheal 
extubation
time to 
sternal 
recumbency
time to
standing
unaided
06 2.5 9.5 13
07 4 7 11
08 7 12.5 22.5
09 7 17 18
10 6 10 11
mean 5.3 11.2 15.1
±sem 0.9 1.7 2.2
Table 3.2.6b
Table 3.2.6a, b - Anaesthetic recovery times (min) - time to endotracheal 
extubation, time to sternal recumbency and time to standing unaided, measured 
from the time the infusion was switched off, for animals in G l (3.2.6a), 
anaesthetised with propofol alone and animals in G2 (3.2.6b) anaesthetised 
with propofol and ketamine.
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Fig 3.2.1- Mean pulse rate (+/-sem), before and during anaesthesia for 
animals which received propofol only (G l) and animals which received 
propofol and ketamine (G2), for induction and maintenance of anaesthesia. 
The infusion started at time 0, immediately after induction of anaesthesia.
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Fig 3.2.2-Mean systolic arterial blood pressure (SABP) (+/-sem), during 
anaesthesia for animals in group 1(G1), which received only propofol and 
animals in group 2(G2), which received propofol and ketamine, for 
induction and maintenance of anaesthesia. The infusion started at time 0, 
immediately after induction of anaesthesia.
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100-1
«—  Gl(n=5)
« —  G2 (n=5)
Time (min)
Fig 3.2.3 - Mean respiratory rate (+/-sem), before and during anaesthesia 
for animals in G l anaesthetised with propofol and animals in G2 
anaesthetised with propofol and ketamine. The infusion started at time 0, 
immediately after induction of anaesthesia. * significantly different from 
G l, P<0.05.
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infusion was switched off, the mean blood propofol concentration was 4.9 ± 0.6 
pg/ml (range 4.1-7.1) (table 3.2.7a). Propofol in blood was detected in all animals 
until 4h after the infusion had been switched off, but in some animals it was 
detected for a further 5h (table 3.2.8; figs 3.2.4 & 3.2.5).
For animals in G2, the mean blood propofol concentration at the time of skin 
incision was 2.2 ± 0.3 pg/ml (range 1.2-2.9). The maximum individual 
concentration of propofol in blood was achieved between 5 and 30 min after the 
start of the infusion and was in the range 2.2 - 4.7 pg/ml; at the time the infusion 
was switched off, the blood propofol concentration was 2.3 ± 0.2 pg/ml (range 1.8- 
2.8) (table 3.2.7b). Propofol was measured in all sheep for 2h after the infusion was 
stopped, but in some animals it was detected for a further 4h (table 3.2.9; figs 3.2.4 
& 3.2.5).
For animals in Gl, the mean area under the concentration-time curve (AUC0bs) for 
propofol was 6.6 ±1.0 pg.h/ml and the mean area under the first moment curve 
(AUMC0bs) was 4.7 ± 0.9 pg.h^/ml. The mean residence time (MRT0bs) was 0.71 
± 0.04 h, mean whole body clearance (CLb) 82 ±11 ml/kg.min and the volume of 
distribution at steady state (Vdss), 3.4 ± 0.5 L/kg. (table 3.2.10a).
The mean AUC0bs for animals in G2, was 2.5 ± 0.3 jig.h/ml and the mean 
AUMC0bs was 1.8 ± 0.2 pg.h^/ml. The mean MRT0bs was, 0.71 ± 0.05 h, mean 
CLb of 129 ± 16 ml/kg.min and mean Vdss, 5.46 ± 0.72 L/kg (table 3.2.10b).
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time
(min)
sheep number
mean ±sem01 02 03 04 05
2 6 4.4 6.2 2.6 1.3 4.1 1.0
5 4.4 4.6 6.5 3.8 2.2 4.3 0.7
10 - - 7.1 4.7 3 4.9 1.2
15 8.4 5.5 6.6 5.2 3.2 5.8 0.8
30 9.8 6.9 4.6 5.4 4.8 6.3 1.0
45 10.3 6.6 4.1 3.9 4.6 5.9 1.2
60 7.1 5.1 4.1 4.1 4.4 4.9 0.6
69 - - - 4.2 -
75 - 5.5 - - -
Table 3.2.7a
time
(min)
sheep number
mean ±sem06 07 08 09 10
2 2.5 1.8 - 1.9 1.3 1.9 0.2
5 2.5 2.4 4.7 2.2 2.0 2.8 0.5
10 1.2 3.3 3.0 2.5 2.1 2.2 0.3
15 1.0 1.7 2.5 3.0 1.2 1.9 0.4
30 1.3 2.3 2.8 3.6 2.2 2.4 0.4
45 1.3 1.7 2.2 2.8 1.6 1.9 0.3
60 1.7 2.4 2.2 2.6 2.8 2.3 0.2
Table 3.2.7b
Table 3.2.7a, b - Blood propofol concentration (pg/ml) during the infusion 
period, for animals in G1 (3.2.7a) which received propofol only and animals in 
G2 (3.2.7b) which received propofol and ketamine for induction and 
maintenance of anaesthesia.
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time
(min)
sheep number
mean ±sem01 02 03 04 05
2 3.2 1.7 2.2 1.8 1.8 2.1 0.3
5 2.3 0.9 1.2 1.1 1.0 1.3 0.3
10 2 0.8 0.7 0.7 0.8 1.0 0.2
15 1.3 0.4 0.6 0.7 0.4 0.7 0.2
30 0.6 0.2 0.2 0.2 0.2 0.3 0.1
45 0.3 0.1 0.1 0.2 0.1 0.2 0.0
60 0.2 0.07 0.07 0.1 0.08 0.1 0.0
90 0.2 0.07 0.05 0.06 0.06 0.08 0.02
120 0.1 0.05 0.03 0.05 0.01 0.05 0.02
180 0.06 0.02 0.02 0.02 0.02 0.03 0.01
240 0.03 0.01 0.01 0.01 0.02 0.02 0.00
360 0.02 ND 0.01 0.01 0.01 0.01 0.00
540 0.01 ND ND ND ND ND ND
1320 ND ND ND ND ND ND ND
1440 ND ND ND ND ND ND ND
Table 3.2.8 - Blood propofol concentration (pg/ml) after the infusion was 
switched off (at time 0), for animals in G1 (n=5) which were anaesthetised 
with propofol.
ND - not detected
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time
(min)
sheep number
mean ±sem06 07 08 09 10
2 0.5 0.6 1.1 1.5 0.9 0.9 0.2
5 0.2 0.3 0.5 0.6 0.5 0.4 0.1
10 0.2 0.2 0.3 0.3 0.3 0.3 0.0
15 0.08 0.4 0.5 0.2 0.3 0.3 0.1
30 0.08 0.1 0.2 0.1 0.2 0.1 0.0
45 0.06 0.06 0.1 0.04 0.1 0.07 0.01
60 0.02 0.05 0.1 0.03 0.08 0.06 0.02
90 0.02 0.06 0.09 0.02 0.04 0.05 0.01
120 0.01 0.03 0.04 0.01 0.04 0.03 0.01
180 ND 0.02 0.03 0.01 0.02 0.02 0.01
240 ND 0.02 0.02 ND 0.02 0.01 0.00
360 ND 0.01 ND ND 0.01 ND ND
540 ND ND ND ND ND ND ND
1320 ND ND ND ND ND ND ND
1440 ND ND ND ND ND ND ND
Table 3.2.9 - Blood propofol concentration (pg/ml) after the infusion was 
switched off (at time 0), for animals in G2 which were anaesthetised with 
propofol and ketamine.
ND - not detected
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sheep n° AUC0bs AUMC0bs MRT0bs CLb Vdss
01 9.9 8.0 0.81 49.7 2.4
02 7.7 5.6 0.73 74.2 3.2
03 5.7 3.3 0.59 73.2 2.6
04 5.1 3.4 0.73 96.7 3.9
05 4.5 3.3 0.71 116.7 5.1
mean 6.6 4.7 0.71 82 3.4
±sem 1.0 0.9 0.04 11 0.5
Table 3.2.10a
sheep n° AUC0bs AUMCobs
M R T ( ) b s
CLb Vdss
06 1.5 0.9 0.59 180.7 6.4
07 2.4 1.8 0.78 127.8 6.0
08 3.1 2.1 0.69 98.2 4.1
09 3.2 2.0 0.62 94 3.5
10 2.3 1.9 0.85 143.8 7.3
mean 2.5 1.8 0.71 129 5.5
±sem 0.3 0.2 0.05 16 0.7
Table 3.2.10b
Tables 3.2.10a, b - Area under the concentration-time curve [(AUC0bs); 
pg.h/ml)], area under the first moment curve [(AUMC0bs)i ^g h2/ml], mean 
residence time [(MRT0bs); h], whole body clearance [(Clb) ml/kg.min] and the 
volume of distribution at steady state [(Vdss); L/kg] of propofol in both G1 
(3.2.10a), anaesthetised with propofol only and G2 (3.2.10b), anaesthetised 
with propofol and ketamine.
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G2 (n=5)
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Fig 3.2.4 -Blood propofol concentration (+/-sem), during the infusion 
period for animals in G l, anaesthetised with propofol only and animals in 
G2 anaesthetised with propofol and ketamine. The infusion started at time 
0, immediately after induction of anaesthesia.
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Fig 3.2.5 - Semilogarithmic plot of blood propofol concentration (+/-sem), 
versus time after the infusion was switched off (at time 0), for animals in G l, 
anaesthetised with propofol only and animals in G2 anaesthetised with propofol 
and ketamine. n=5 except where indicated in parentheses.
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4. DISCUSSION
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4.1 Degradation and interactions of propofol with other 
drugs in vitro
Several problems were encountered in the studies of propofol degradation by 
microsome preparations. Firstly, to date there are only two reports in the literature 
on drug metabolism in vitro involving propofol, neither of which reported the 
measurement of propofol (Janicki et al., 1992; Baker et al., 1993). Moreover, both 
of these groups used only one incubation time point, 15 and 45 min respectively, in 
studies of the effect of propofol on drug metabolism. Consequently, it was 
necessary to carry out a pilot study to optimise the incubation conditions. Although 
tissue from only one animal was used for each incubation time point, the data 
demonstrated clearly that the oxidative degradation of propofol by rat hepatic 
microsomes was rapid. This highlighted a second potential problem. Since the 
amount of propofol degraded even after 5 min of incubation was in excess of 5%, 
standard calculations of enzyme kinetic constants were not possible as the 
conditions of the reaction did not comply with the assumptions on which the 
Michaelis Menten equation are based (Segel, 1975). In order to obtain linear 
kinetics and calculate the maximal velocity, Vmax, and the Michaelis constant, Km, 
the reaction must proceed to a negligible extent during the course of the assay (<5% 
of substrate used). If a substantial fraction of the substrate is used during the assay, 
the Km and Vmax values determined from the reciprocal plot of velocity against 
substrate concentration will be in error. However, in 1971, Lee & Wilson showed 
that the arithmetic mean substrate concentration, ^([So] +[St]) where So is the 
initial substrate concentration and St is the substrate concentration at the incubation 
time, t, is an excellent approximation of the substrate concentration and with this 
value the modified Lineweaver Burk plot can yield reliable estimates of the kinetic 
constants Vmax and Km even when the reaction has proceeded to a considerble 
extent (circa 4% error with 50% substrate utilization).
The kinetic constants in these studies were obtained by using the modified 
Lineweaver Burk equation , therefore, the percentage error in the results obtained is 
likely to be small. An incubation time of 15 min was chosen in an attempt to permit 
drug interaction studies to yield reliable data. For further studies with propofol in 
hepatic microsome preparations, the most appropriate incubation time would be set 
to 5 min or less, although in practice this is difficult for technical reasons.
It was also observed in this study that when the incubation time was greater than 30 
min, the concentrations of propofol remaining were very variable and inconsistent, 
probably due to instability of the mixture, but further studies are necessary to
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support this suggestion, since the incubation was only carried out once. However, 
these preliminary data cast some doubt on the consistency of the results reported by 
Janicki et al. (1992) who used a 45 min incubation time when studying the effects 
of propofol on the degradation of alfentanil and sufentanil by liver microsomes from 
pigs and humans.
The rate of degradation of propofol was proportional to the concentration which is 
in accordance with that predicted by the Michaelis Menten equation. The decrease 
on the rate of propofol degradation with time was presumably due to the decrease in 
the saturation of the enzyme, however, it could have been due to product inhibition. 
This highlighted a third problem encountered with studies on propofol degradation 
in vitro. The degradation of propofol was measured on the basis of substrate 
disappearance and not product formation. Ideally the accumulation of one or more 
products of propofol degradation would be desirable. This would have allowed 
better enzyme kinetic analyses, and a study of the ratio of substrate disappearance 
and product formation. Furthermore, it would have been desirable to study the 
possibility of product inhibition of cyto P450. However, it was not possible to 
obtain reference standards of the metabolites due to the difficulty in synthesising 
these compounds (I. Cockshott, personal communication). It has been shown that 
the major metabolites of propofol in humans and animals are propofol glucuronide 
and the glucuronic and sulphate conjugates of its hydroxylated metabolite (Simons 
et al, 1988, 1991a,b), although the proportion of metabolites produced varies with 
species. However, no information on what metabolites were produced, their time 
course of production or the effect of drug interactions on specific metabolites was 
acquired from the studies reported here.
The concentrations of propofol used in these studies were intended to reflect a range 
of blood propofol concentrations including those which would be encountered 
during anaesthesia and those which would allow determination of Km and Vmax. 
The concentrations of substrate chosen to generate the reciprocal plot, should be 
around the Km value, otherwise accurate determinations are not possible. The mean 
Km values recorded for rat hepatic tissues ranged from 43.6pM - 48.9pM and the 
range of concentrations used during incubation spanned this value.
In humans, there appears to be a wide variation in blood concentrations of propofol 
associated with the induction of sleep and the abolition of responses to surgical 
stimuli, with the concurrent use of other drugs making comparisons difficult 
(Spelina et al., 1986; Schafer et al., 1988; Dixon et al., 1990). In human volunteers, 
the blood concentration required to induce sleep varied from as low as 1.64 (ig/ml to 
as high as 6.38 pg/ml (Schuttler et a l, 1985), which correspond to 9pM and 37pM
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respectively, while the blood concentrations required to abolish responses to 
surgical stimulation in humans appear to be in excess of 5pg/ml (29pM) (Turtle et 
al.9 1987). In dogs undergoing superficial body surface surgery, blood propofol 
levels in excess of 5pg/ml were also required to maintain satisfactory surgical 
conditions (Nolan and Reid, 1993), while in female rats, liver propofol 
concentrations as high as 132pM are achieved following a single anaesthetic dose 
(Simons et al., 1991a). Thus, it was considered appropriate to choose the 
concentration range from 28pM to 140pM in rat microsome studies.
It has been shown in vivo that species variations in the persistence of propofol in 
blood following i.v. administration exist. In goats, Reid et al. (1993) did not detect 
propofol in blood 2h after bolus administration, while in rats, dogs and humans, 
propofol can still be detected 8 h or later after the end of administration (Cockshott 
et al.9 1990; Simons et al.9 1991a; Nolan & Reid, 1993). These differences are 
probably the result of species variation in the capacity to metabolise propofol. In 
this study, no significant difference was observed between the rate of propofol 
degradation by microsomal hepatic cyto P450 obtained from rat and sheep. The Km 
values for rats and sheep were similar (42.0 ± 7. lpM in sheep; 48.9 ± 2.2pM in rat), 
and confirm the similarities that exist between these species for cyto P450 oxidative 
metabolism in vitro (see review by Smith, 1991).
Of interest was the observation that Sprague Dawley rats degraded propofol more 
rapidly than Wistar rats. This observation was based on a small number of animals, 
however, it indicated the possibility that breed differences may exist in the ability of 
animals to metabolise propofol. Recent work by Zoran et al. (1993) reported 
significant differences in the whole body clearance of propofol between greyhounds 
and mixed breed dogs in vivo; the clearance rate for greyhounds was half that 
obtained in mixed breed dogs (54.0 ± 10.0 ml/kg.min cf 114.8 ± 50.0 ml/kg.min), 
although, the value reported for greyhounds is comparable to that obtained for 
mixed breed dogs by Nolan et al. (1993). Strain differences in the metabolism of 
hexobarbitone have been observed in mouse, manifested as increased sleeping time 
after a single dose (Alvan, 1992). Thus, despite the lack of significant differences 
between sheep and rat in the rate of degradation of propofol and the affinity of 
cytochrome P450 for propofol recorded in this study, the possibility exists of other 
interspecies and interbreed variation in propofol degradation.
At concentrations equal or greater than 10 mM, 1-aminobenzotriazole (ABT) has 
been shown to inhibit (by alkylation of the prostetic heme) by approximately 70% 
the activity of several isoenzymes of cyto P450, with no detectable effect on other
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components of the endoplasmic reticular mixed function oxidase systems such as 
NADPH cytochrome c reductase (FMO) and cytochrome b5 (Mugford et al., 1992).
The inhibition of cyto P450 with ABT, 12 mM, caused a dramatic reduction in the 
rate of propofol degradation which suggests that the oxidative degradation of 
propofol is extensively cyto P450-dependent within hepatic microsomes. The degree 
of inhibition observed was dependent on the concentration of propofol used, less 
inhibition of propofol degradation at higher initial concentrations of propofol, which 
suggests that the inhibition is competitive.
The identities of isoenzymes that catalyse ABT metabolism have not yet been 
extensively studied, however, ABT appears to affect isoenzymes responsible for 
ethoxycoumarin and ethoxyresourfin O-deethylation (P450 1A & 2B) and lauric 
acid hydroxylation (P450 4A1) (Mugford et al., 1992). These workers indicated that 
there are P450 isoenzymes which are not affected by ABT, however, their identities 
are still unknown. There is a need for further enzymatic studies to clarify whether 
the residual rate of degradation of propofol observed in the presence of ABT is a 
result of degradation from P450 subfamilies which do not recognise ABT as a 
substrate, or whether there is a contribution from other enzymatic systems such as 
the flavin-monooxigenase system (FMO). However, it is clear that an enzymatic 
dependence exists between the isoenzymes inhibited by ABT and the degradation of 
propofol.
Inhibition of cyto P450 activity of rat hepatic microsomes by propofol was reported 
by Baker et al. (1993). They found propofol (25pM - lOOOpM) to be a dose 
dependent inhibitor of benzphetamine demethylation and aniline hydroxylation in 
rat liver microsomes at concentrations of 25 pM and higher, but to be ineffective at 
inhibiting enflurane metabolism. Benzphetamine is metabolised by the isoenzyme 
P450 2B1, and aniline by P450 2B1 and to a small extent by P450 2C6. while 
enflurane is metabolised by P450 2E1. The objective of their work was to identify 
the effectiveness and selectivity of propofol in inhibiting drug metabolism and they 
demonstrated that propofol could function as an effective and selective inhibitor of 
drug metabolism. Because the greatest degrees of propofol inhibition occurred in 
microsomes from phenobarbitone - treated animals, they demonstrated that propofol 
was most effective at inhibiting the isoenzymes P450 2A1 and P450 2B1, 
phenobarbitone - inducible forms of cytochrome P450. It is worth commenting that 
the incubation of propofol with hepatic microsomes for 15 min would probably 
result in a considerable decrease in the ’actual' propofol concentration, and therefore 
it is possible that these workers have underestimated the capacity of propofol to 
inhibit these isoenzymes, since they did not measure propofol concentrations.
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Propofol dose - dependently inhibited the N-demethylation of aminopyrine by rat 
hepatic microsomes. Concentrations as low as 5.6pM did not significantly interfere 
with aminopyrine N-demethylation, but the inhibition (mean, 34.9%) was effective 
at doses of 56 pM, a concentration achievable during clinical anaesthesia. The 
broad, yet selective capacity of propofol to inhibit the activity of cyto P450 
isoenzymes has many implications for the concomitant use of drugs during propofol 
anaesthesia in vivo. It is also possible that the interaction of propofol with different 
enzyme sites may vary and that inhibition at one isoenzyme might be competitive, 
while at other sites, noncompetitive inhibition might occur. These possibilities need 
to be studied further with selective ligands, inhibitors and inducers for the particular 
isoenzymes involved. Thus, it appears likely that propofol has the potential to alter 
drug metabolism, depending on the drug administered and its metabolic pathway.
Aminopyrine significantly inhibited the degradation of propofol, and significantly 
increased the Km value for propofol without affecting Vmax, indicating that the 
inhibition was competitive in nature. Further studies are necessary to determine 
whether aminopyrine combines to the active site of the enzyme which degrades 
propofol (true competitive inhibition), thus indicating that aminopyrine and propofol 
share the same isoenzymes for degradation, or whether it binds to a site other than 
the active one (feedback inhibition). The data obtained from the studies with ABT 
and aminopyrine thus suggest that the P450 2B and 2C isoenzymes are involved in 
the oxidative degradation of propofol since aminopyrine is preferentially 
metabolised by the isoenzyme P450 2C11.
Ketamine and alfentanil are drugs which are potentially suitable for use in 
conjunction with propofol. Both ketamine and alfentanil undergo extensive hepatic 
metabolism, both are metabolised by cytochrome P450 and demethylation is the 
major pathway for both drugs. Ketamine also undergoes hydroxylation, while 
dealkylation and aromatic hydroxylation occur during the metabolism of alfentanil 
(Waterman & Livingston, 1978b; Meuldermans et al., 1987). Since both ketamine 
and alfentanil undergo demethylation, and propofol degradation is inhibited by 
aminopyrine, an effective substrate for demethylation processes, it was considered 
possible that either of these drugs might inhibit propofol metabolism. These drugs 
were used at one concentration only, one that would reflect clinically effective 
plasma concetrations. Alfentanil plasma concentrations between 148 and 285 ng/ml 
have been reported to be clinically satisfactory in combined infusions with propofol 
(Schuttler et al., 1988), consequently, a concentration of 200 ng/ml was chosen for 
study, while the ketamine concentration used was 5 pg/ml, since Waterman & 
Livingston (1978b) indicated that sheep awake from ketamine anaesthesia at plasma 
concentration of approximately lpg/ml. The consequences of inhibition of propofol
96
degradation in vivo would be to raise propofol blood levels and prolong anaesthesia. 
Indeed, Gepts et al (1988) reported that when propofol and alfentanil were used 
together to maintain anaesthesia, the activity of each drug was potentiated. Neither 
ketamine nor alfentanil, had a significant effect on the microsomal hepatic oxidative 
degradation of propofol. Ketamine increased the Km value for propofol (mean 
values, 46.5pM to 53.2pM), but this difference was not significant, while alfentanil 
did not change either the Vmax or the Km of propofol. Janicki et al. (1992), 
reported that propofol inhibited dose-dependently (3pM - lOOpM) the oxidative 
metabolic degradation of alfentanil and sufentanil by hepatic microsome 
preparations from pig and humans. The major metabolite of propofol is formed by 
hydroxylation of its phenol ring and alfentanil also undergoes some hydroxylation, 
therefore, it is possible that the interactions between propofol and alfentanil involve 
cyto P450 isoenzymes which perform hydroxylation reactions. However, since 
hydroxylation is not the major pathway for alfentanil degradation (Meuldermans et 
al., 1987), it is considered unlikely that significant interference of alfentanil with 
propofol degradation will occur in vivo unless very high doses of alfentanil are used. 
Indeed work in vivo has suggested that alfentanil does not affect significantly the 
pharmacokinetics of propofol (Browe et al., 1992; Bostek et al., 1992).
Ketamine did not alter the degradation of propofol by liver microsomes, which 
suggests that the isoenzymes responsible for propofol degradation do not have a 
high affinity for ketamine, and that no interaction between the two drugs in vivo is 
likely to occur. However, it is known that ketamine induces liver enzymes in vivo, 
increasing its own metabolism (Livingston & Waterman, 1978), therefore, the 
potential for alteration of propofol metabolism by ketamine in whole animals cannot 
be totally excluded. It would be of interest to test this potential in vitro using 
hepatocellular cultures, since such tissue cultures have the potential to display liver 
enzyme up- and down-regulation, which cannot occur with microsome preparations.
There are many studies indicating that the lung plays an active role in the uptake 
and metabolism of drugs (Orton et al., 1973). The in vitro study with rat lung 
microsome preparations confirms speculation from studies in vivo, which suggested 
that the high clearance of propofol might be due to an extra hepatic site of 
metabolism (Lange et al., 1990; Veroli et al., 1992). The data reported here indicate 
that lung tissue can degrade propofol and it is considered likely that this is one of 
the sites which contributes to the high body clearance of propofol in vivo, at least in 
rats. The mean Km value, 13pM, indicates that the affinity of propofol for the 
enzyme degrading it is high and is similar to the affinity of propofol for hepatic 
microsomal enzymes. However, the range of Km values was large, from 2.9pM - 
30.2 pM and further work should be done to characterise the enzyme kinetics in this
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tissue. Since there is interspecies differences in the degradation of xenobiotics, it 
cannot be assumed that propofol is degraded by the lung in all species. It is difficult 
to estimate the contribution of lung tissue to the degradation of propofol compared 
with hepatic tissue, since the concentration of protein in the lung was much lower 
than the liver (and the concentrations of propofol used were also lower). Matot et al. 
(1993), reported that in cats there is a substantial extraction of propofol by the lung, 
therefore, it is important to consider the potential for drug metabolsim in this tissue. 
Moreover, the lung is an organ which receives a high blood flow (equivalent to 
cardiac output), and consequently could help account for the high body clearance 
reported in species such as the goat (Reid et a l , 1993). Further studies are required 
to characterise and quantify lung metabolism of propofol in vitro.
4.2 Pharmacokinetics and pharmacodynamics of propofol 
and propofol/ketamine infusions in sheep.
In vitro techniques for studying drug metabolism have been developed for scientific, 
economical and ethical reasons, and the information generated from such work is 
useful. However, in vitro alternatives generally cannot replace whole animal 
experiments, but they provide clear indications for subsequent in vivo research. The 
results obtained from the degradation of propofol and the apparent lack of effect of 
ketamine on propofol metabolism in vitro suggested that this drug combination 
might be suitable to study in vivo. Consequently the use of propofol/ketamine 
infusions was studied qualitatively i.e. suitability for body surface surgery, and 
quantitatively, by characterising the kinetics and dynamics of propofol when 
coadministered with ketamine. Sheep were considered to be an appropriate model 
for this purpose. Firstly, data obtained from in vitro studies indicated that there are 
no observed difference in the Km and Vmax values for sheep and rats; secondly, the 
practicalities of TIVA and repeat blood sampling indicated that rats would be 
difficult to handle, and thirdly, the pharmacokinetics of ketamine in sheep indicated 
that it was rapidly metabolised (Waterman & Livingston, 1978b) and thus might be 
a useful agent to administer by infusion.
To date, there is a lack of information on the concomitant use of propofol and 
ketamine for anaesthesia, only two reports in humans have been found (Mayer et 
al., 1990; Schuttler et al., 1991). Both groups reported that total intravenous 
anaesthesia with propofol and ketamine was very satisfactory and that propofol and 
ketamine induced fewer disturbances in physiological parameters than total 
intravenous anaesthesia with propofol and fentanyl.
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General anaesthesia in ruminant animals is associated with the risk of regurgitation 
of ruminal contents which may lead to aspiration pneumonia and death (Hall & 
Clarke, 1991). The rapid recovery from anaesthesia in sheep given a bolus dose of 
propofol before maintenance of anaesthesia with halothane (Waterman, 1988), 
indicated the potential for use of propofol in a total intravenous anaesthetic 
technique in this species, where a rapid recovery from anaesthesia is essential. 
Many regimens of anaesthesia have been suggested as being suitable for use in 
small ruminants (Taylor, 1991), however none of those discussed included TIVA. 
The use of a variable infusion rate was considered important and of more clinical 
value than using a constant-rate infusion, because it permits the anaesthetist to 
titrate the intravenous dose to a desired effect, according to the status of each 
individual animal.
The initial infusion rate of propofol alone, 0.5 mg/kg/min, was based on data and 
clinical experience gained by Nolan & Reid (1993) in dogs undergoing the same 
surgical procedure, and premedicated with the same drug combination. It was 
anticipated that ketamine would have a propofol-sparing effect and consequently, 
the initial propofol infusion rate for sheep receiving propofol and ketamine was 
lower, 0.3 mg/kg/min. The combination of an induction dose of propofol, 4mg/kg, 
followed by a variable infusion rate was satisfactory clinically for superficial 
surgery in sheep. Similarly, an induction dose of propofol, 3 mg/kg, and ketamine, 1 
mg/kg, and a variable infusion of the two drugs proved satisfactory for induction 
and maintenance of anaesthesia. In both groups, the first skin incision was made 10 
min after the infusion began, and the degree of analgesia appeared to be 
satisfactory. Reid et al. (1993), reported that a bolus dose of 4 mg/kg was 
satisfactory for induction of anaesthesia in goats, where anaesthesia was maintained 
with a gaseous anaesthetic, while previously, Waterman (1988) had indicated that a 
mean propofol induction dose of 3.8 mg/kg was satisfactory in sheep. Nolan & Reid 
(1993) reported that induction of anaesthesia with propofol 4 mg/kg prior to 
maintenance with a zero order infusion of propofol (0.4 mg/kg/min) and 67% 
nitrous oxide was satisfactory for superficial surgery in dogs, although these authors 
commented that this anaesthetic regime induced 'light' surgical anaesthesia. The 
inclusion of ketamine allowed a sparing of the dose of propofol necessary for 
induction and maintenance of anaesthesia. Although infusion rates were adjusted 
according to clinical need and physiological status, no other attempt was made to 
equate the plane of anaesthesia in both groups. Indeed it is considered unlikely that 
the depth of anaesthesia in both groups was the same, and it is possible that the total 
dose of propofol used in sheep receiving ketamine could have been reduced further. 
One animal in the propofol group and two in the propofol/ketamine group were 
apnoeic after induction of anaesthesia, but spontaneous breathing resumed shortly
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after manual ventilation was performed. The higher incidence of apnoea in sheep 
receiving propofol/ketamine than in the propofol group might suggest that the 
animals were not in the same plane of anaesthesia and that a smaller dose of 
propofol would have been adequate. However, apnoea post induction is a normal 
feature during propofol anaesthesia in humans and animals (Morgan & Legge, 1989; 
Watkins et al., 1987; Nolan et al., 1993) and the group numbers were small (n=5).
The quality of anaesthesia was satisfactory in both groups of sheep and no reaction 
to the surgical procedures was observed. Both systolic arterial blood pressure and 
pulse rate, indicators of cardiovascular function, were well maintained throughout 
the infusion period. In both groups there was an increase of approximately 15% 
from the value taken before induction, for the pulse rate 5 min after the infusion 
began, while 30 min after the infusion began, the systolic arterial blood pressure had 
fallen in both groups by approximately 15% from the value taken at the start of the 
infusion. Mild hypotension is a feature of propofol anaesthesia in humans (Langley 
& Heel, 1988), although this is dose dependent.
The respiratory rate was significantly higher during the infusion period for animals 
in the propofol/ketamine group compared to those sheep that received propofol 
alone, possibly due to the inclusion of ketamine, since respiratory depression was 
not recorded in the other group. Respiratory depression is not a feature of clinical 
doses of ketamine (White et al., 1982), but is often associated with propofol 
anaesthesia. Repiratory rate is a fairly crude marker of respiratory function and 
arterial blood gas analysis or end tidal carbon dioxide concentration recordings 
would have been more informative.
Schuttler et al. (1988) & Puttick et al. (1992) showed that marked individual 
variations in blood concentrations of propofol regularly occur during infusion of 
propofol, a finding observed similarly in dogs by Nolan & Reid (1993). In this study 
there were variations in blood concentrations of propofol and in the time of 
achievement of maximal blood concentrations, however, this was probably a 
reflection of differences in individual infusion rates. The use of a variable infusion 
rate determined by clinical and cardiovascular parameters was surprisingly 
successful in achieving a steady state blood propofol concentration in both groups 
of sheep. The levels of ketamine in plasma were not measured and it is not known if 
steady state levels of this drug were also achieved with the total amount infused.
The persistence of propofol in blood, in these sheep (last detectable propofol, 9h) 
was less than the 25h reported for dogs undergoing propofol infusion for a similar 
period (Nolan & Reid., 1993), suggesting that sheep metabolise propofol faster than
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dogs. This has also been previously reported for the barbiturate anaesthetic, 
pentobarbitone (Rae, 1962).
The recovery times observed in sheep anaesthetised with propofol alone were 
markedly shorter than those reported by Nolan & Reid in dogs (1993), 2.8 ± 0.4 cf
7.6 ±1.0 min for endotracheal extubation, 6.3 ± 1.2 cf 20.8 ± 6.3 min for sternal 
recumbency and 10.9 ± 1.6 cf 30.7 ± 8.0 min for standing unaided for sheep and 
dogs respectively. Sheep that received propofol and ketamine took significantly 
longer to be extubated and to roll into sternal recumbency than sheep that had been 
anaesthetised with propofol alone, but there were no differences in the time to 
standing. This may indicate that the plasma ketamine concentrations as the infusion 
was switched off were higher than necessary and highlights the need to measure 
plasma concentraions of all drugs administered in a multi-drug infusion technique.
Pharmacokinetic analysis of the data showed propofol to have a large volume of 
distribution in sheep. The volume of distribution at steady state (3.4 ±0.5 L/kg) was 
greater than that reported in goats, 2.56 ± 0.32 L/kg (Reid et al., 1993), but smaller 
than reported for dogs, 6.51 ± 0.52 L/kg (Nolan & Reid, 1993). The clearance of 
propofol in goats (275.0 ± 38.5 ml/min.kg) is higher than that obtained for sheep 
receiving propofol alone in this study (82 ± 11 ml/kg.min), however, propofol in 
sheep is more rapidly cleared than in dogs, 50.1 ±3.9 ml/kg.min (Nolan & Reid, 
1993), and in humans, 2.09 ± 0.65 L/min (Shafer et al., 1988). No significant 
differences were recorded between the two goups of sheep although the mean whole 
body clearance of propofol and the Vdss was higher for sheep that received 
ketamine. These data suggest that ketamine does not alter the pharmacokinetics of 
propofol in sheep. However, in this study the total dose of propofol administered 
was lower in the group which received propofol/ketamine than in the group that 
received propofol alone and although other workers have reported that propofol 
does not exhibit dose-dependent pharmacokinetics (Gepts et al., 1987), further 
studies are necessary to confirm this in sheep. In addition, only 5 animals were 
included in each group and if larger numbers were used, significant differences in 
whole body clearance and Vdss may have been demonstrated.
In conclusion, the studies reported in this thesis, suggest that the rapid recovery 
observed from propofol anaesthesia is related to the high rate of degradation of this 
drug by the hepatic enzyme systems, and suggest that the lung may be an important 
organ in degrading propofol. Cytochrome P450 enzymatic systems have an 
important role in propofol degradation and it is hypothesised that P450 2B and 2C 
subfamilies are involved in the degradation of propofol. Since the degradation of 
propofol in microsomes was extremely rapid, it would be interesting to study the
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degradation of propofol by hepatocellular cultures where both microsomal and 
cytosolic enzymatic systems are present, intracellular drug distribution takes place 
and inhibition/induction studies can be monitored. Secondly, it is clear that 
propofol, at concentrations found in blood during clinical anaesthesia, has the 
potential to influence significantly the rate of metabolism of other drugs and vice 
versa. However, these potential interactions have to be evaluated on the basis of the 
individual drugs coadministered with propofol. Finally, it is important to emphasise 
that propofol alone or when combined with other drugs is potentially very useful for 
total intravenous anaesthesia, and that propofol/ketamine infusions are worthy of 
further development in animal species.
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APPENDIX
121
animal n° protein cyto P450
R1 16 1.0
R2 17 0.99
R3 14 1.0
R4 16 0.54
R5 17 0.65
R6 18 0.92
R7 17 0.65
Table A l - Concentration of protein (mg/gr of liver) and Cytochrome P450 
(cyto P450; nmol/mg of protein) of hepatic microsome preparations, from rats 
used in the study of the time course of the degradation of propofol by hepatic 
microsomes. The rats from R1-R7 were used for incubations corresponding to 
5, 10, 15, 20, 30, 45 and 60 min respectively.
animal n° protein cyto P450
R1 16 1.0
R2 17 0.9
R3 16 0.7
R4 15 0.6
R5 14 0.69
R6 17 0.52
Table A2 - Concentration of protein (mg/gr of liver) and Cytochrome P450 
(cyto P450; nmol/mg of protein) of hepatic microsome preparations, from rats 
used in the study of the inhibition of cytochrome P450 activity by of propofol.
122
animal n° protein cyto P450
R1 18 0.54
R2 16 0.88
R3 17 0.6
R4 15 0.66
R5 15 0.61
R6 14 0.58
Table A3 - Concentration of protein (mg/gr of liver) and Cytochrome P450 
(cyto P450; nmol/mg of protein) of hepatic microsome preparations, from rats 
used in the study of the possibility of extra cytochrome P450 degradation of 
propofol.
123
animal n° protein cyto P450
R1 15 0.72
R2 16 0.76
R3 15 0.89
R4 15 0.51
R5 16 0.69
R6 16 0.6
R7 15 0.71
R8 14 0.49
R9 16 0.47
RIO 14 0.6
R ll 16 0.83
R12 15 0.67
R13 16 0.78
R14 15 0.48
R15 15 0.51
R16 15 0.61
R17 14 0.59
R18 14 0.78
Table A4 - Concentration of protein (mg/gr of liver) and Cytochrome P450 
(cyto P450; nmol/mg of protein) of hepatic microsome preparations, from rats 
used in the study of the effect of other drugs on the cytochrome P450 
degradation of propofol. Animals R1 to R6 were used in experiments with 
propofol and ketamine; R7 to R12 in experiments with propofol and alfentanil 
and from R13 to R18 in experiments with propofol and aminopyrine.
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animal n° protein cyto P450
SI 19 0.66
S2 19 0.49
S3 18 0.54
S4 15 0.62
S5 20 0.59
S6 19 0.60
Table A5 - Concentration of protein (mg/gr of liver) and Cytochrome P450 
(cyto P450; nmol/mg of protein) of hepatic microsome preparations, from rats 
used in the study of the degradation of propofol by sheep cytochrome P450 
enzymatic system (a comparison with sheep).
animal n° protein
R1 1
R2 1.25
R3 1.83
R4 1.5
R5 1.9
Table A6 - Concentration of protein (mg/gr of liver) and Cytochrome P450 
(cyto P450; nmol/mg of protein) of hepatic microsome preparations, from rats 
used in the study of the degradation of propofol by lung cytochrome P450 
enzymatic system
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In.
Cone
05
min
10
min
15
min
20
min
30
min
28 16 15 15 14 14
56 36 36 33 32 29
84 60 57 56 51 46
140 112 107 101 99 84
Table A7 - Initial propofol concentration (In. Cone, pM) and propofol 
concentrations (pM) used for the graphical representations of the velocity of 
propofol degradation plotted against propofol concentrations in the study of the 
time course (5, 10, 15, 20, 30 min) of propofol degradation by rat hepatic 
microsomes.
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I .e . R1 R2 R3 R4 R5 R6 mean ±sem
28 18.1 15.6 18.2 17.6 14.9 15.8 16.7 0.6
56 41.3 37.0 45.8 42.5 34.72 37 39.7 1.7
84 67.3 61.7 70.7 67.5 57.6 60.2 64.2 2.1
140 120.6 120.6 127.3 118.5 110.2 112.8 118.3 2.5
28* 24.8 24.6 27.1 26.9 27.5 25.8 26.1 0.5
56* 51.5 52.2 56.8 54.4 53.4 51 53.2 0.9
84* 77.8 79.9 79.9 79.7 81.3 77.6 79.4 0.6
140* 136.9 135.5 140.2 136 133.3 129.5 135.2 1.5
Table A8 - Initial propofol concentration (I.C., pM) and propofol 
concentrations (pM) used for the graphical representations of the velocity of 
propofol degradation plotted against propofol concentrations in the study of 
propofol degradation by rat hepatic microsomes in the presence or absence of 
1-aminobenzontriazole (*).
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I.C. R1 R2 R3 R4 R5 R6 mean ±sem
28 14.1 14.7 14.7 14.9 14.7 14.7 14.6 0.1
56 28.9 32.0 32.9 34.2 32.3 32.2 32.1 0.7
84 46.4 52.0 55.5 54.5 54.1 52.3 52.4 1.3
140 86.2 97.7 103.6 105.0 101.2 99.7 98.9 2.7
28* 14.2 14.9 14.9 15 15.1 14.9 14.8 0.1
56* 29.8 32.3 33.7 34.8 33.3 32.8 32.8 0.7
84* 47.1 52.5 55.3 56.2 54.7 53.2 53.2 1.3
140* 86.9 96.5 103.3 105.5 100.1 98.0 98.4 2.7
Table A9 - Initial propofol concentration (I.C, pM) and propofol 
concentrations (pM) used for the graphical representations of the velocity of 
propofol degradation plotted against propofol concentrations in the study of the 
degradation of propofol by rat hepatic microsomes in the absence or in the 
presence of ketamine (*).
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I.e. R1 R2 R3 R4 R5 R6 mean ±sem
28 15.2 15.9 16.4 14.6 15 15.7 15.5 0.3
56 34.5 36 37.2 32 32 36.2 34.6 0.9
84 59.3 61.6 59.9 50.6 54.9 58.2 57.4 1.6
140 114.8 111 111 93.6 102.8 107.9 106.8 3.1
28* 15.2 15.6 16.5 14.7 15.1 15.8 15.5 0.2
56* 34.6 35.8 36.1 32.0 33.5 34.8 34.5 0.6
84* 59 62.2 59.2 50.6 53.5 57.3 57.0 1.7
140* 117.4 123.8 110.2 91.0 102.6 108.5 108.9 4.8
Table A10 - Initial propofol concentration (I.C, pM) and propofol 
concentrations (pM) used for the graphical representations of the velocity of 
propofol degradation plotted against propofol concentrations in the study of the 
degradation of propofol by rat hepatic microsomes in the absence or in the 
presence of alfentanil (*).
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I.e . R1 R2 R3 R4 R5 R6 mean ±sem
28 14.8 14.8 14.5 14.0 14.7 14.6 14.6 0.1
56 33.7 33.5 33 34.4 33.1 31.7 33.2 0.4
84 53.7 59.4 52.9 56.0 55 50.5 54.6 1.2
140 104.2 111 99 112 102.4 92.8 103.6 3.0
28* 17.4 17.7 17.1 18.5 16.9 16.9 17.4 0.2
56* 37.9 39.4 37.2 40.8 35.6 35.4 37.7 0.9
84* 60.6 64.1 58.4 62.0 59.5 55.8 60.1 1.2
140* 109.1 115.1 109.6 114.2 107.1 99.2 109.0 2.3
Table A ll  - Initial propofol concentration (I.C, pM) and propofol 
concentrations (pM) used for the graphical representations of the velocity of 
propofol degradation plotted against propofol concentrations in the study of the 
degradation of propofol by rat hepatic microsomes in the absence or in the 
presence of aminopyrine (*).
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I.e . R1 R2 R3 R4 R5 R6 mean ±sem
28 16.4 14.3 14.6 14.2 14.1 14.0 14.6 0.4
56 41.5 33.2 33.0 31.8 29.7 28.4 32.9 1.9
84 73.7 54.7 55.4 53.3 49.5 48.0 55.8 3.8
140 124.6 106.4 109.1 101.8 99.1 98.7 106.6 4.0
28* 15.2 15.9 16.4 14.6 15 15.7 15.5 0.3
56* 34.5 36 37.2 32 32 36.2 34.6 0.9
84* 59.3 61.6 59.9 50.6 54.9 58.2 57.4 1.6
140* 114.8 111 111 93.6 102.8 107.9 106.8 3.1
Table A12 - Initial propofol concentration (I.C, pM) and propofol 
concentrations (pM) used for the graphical representations of the velocity of 
propofol degradation plotted against propofol concentrations in the study of the 
degradation of propofol by sheep and rat* hepatic microsome preparations.
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I.C. R1 R2 R3 R4 R5 mean ±sem
5.6 4.8 4.4 4.5 5.1 5.0 4.8 0.1
11 8.5 8.1 8.4 9.3 8.9 8.6 0.2
28 16.6 17.0 17.6 20.0 19.1 18.1 0.6
56 28.8 31.9 31.2 37.1 35.0 32.8 1.5
Table A13 - Initial propofol concentration (I.C, pM) and propofol 
concentrations (pM) used for the graphical representations of the velocity of 
propofol degradation plotted against propofol concentrations in the study of the 
degradation of propofol by rat lung microsome preparations.
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